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Modulating Antitumor T Cell Responses using Cytomegalovirus-based Vaccines  
 
Jeremy Michael Grenier, PhD 
University of Connecticut 2019 
 
Cytomegalovirus (CMV) is a ubiquitous herpes virus that generates a unique T cell response, 
characterized by the maintenance of a high frequency of virus-specific T cells over the lifetime 
of the host.  This prolonged T cell response makes CMV an attractive vaccine platform.  Our lab 
has previously generated a recombinant murine CMV (MCMV) expressing a modified 
melanoma antigen, MCMVgp100KGP, which protects mice from tumor challenge.  In Chapter 3 
of this current study, we hypothesized that CMV vectors expressing multiple tumor antigens 
would be more effective vaccines in the treatment of melanoma.  However, our data show that 
novel MCMV vectors expressing two melanoma antigens do not delay tumor growth compared 
to MCMVgp100KGP, highlighting the difficulty in targeting shared tumor antigens.   
In Chapter 4, we sought to improve the efficacy of MCMVgp100KGP by combination 
immunotherapy.  Herein, we show that adoptive cell therapy enhances the antitumor effects of 
MCMV-based vaccines.  MCMVgp100KGP maintains adoptively transferred cells at higher 
frequencies than an acute viral vector, but fails to eradicate established tumors.  In response to 
vaccination with MCMVgp100KGP, several immunosuppressive molecules including PD-L1, 
Qa-1b, and IDO1 are upregulated within the tumor microenvironment, suggesting several   
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mechanisms of tumor resistance.  Surprisingly, blockade of these molecules did not improve the 
antitumor activity of MCMVgp100KGP vaccination.  This data further calls into question the 
reliability of PD-L1, Qa-1b, and IDO1 expression as predictive markers for response to therapies 
targeting these pathways.  In the context of vaccination, these molecules may serve as indicators 
of effective vaccination rather than predictive biomarkers for combination immunotherapy. 
Lastly, this study also identifies a novel population of CD169+ tumor associated macrophages 
(TAMs).  In Chapter 5, we characterize a population of CD169+ TAMs found within the 
melanoma tumor tissue.  This population expresses higher levels of MHCII and CD80, 
suggesting a potential to prime antitumor T cells.  Preliminary data also suggests that CD169+ 
TAMs may preferentially phagocytose tumor cell fragments directly within the tumor bed.  
Future work will determine the role of these TAMs in priming antitumor T cells and regulating 
antitumor immunity.
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Chapter 1: Introduction 
1. Evidence of Tumor-Immune Interactions 
Immunotherapy of cancer has been a long-sought goal of scientists and oncologists which until 
recently, had been largely discredited as a viable treatment modality for cancers unassociated 
with infectious agents.  Some of the earliest clinical studies utilizing a form of immunotherapy 
for the treatment of cancer were performed by Dr. William Coley in the late 1800’s.  Inspired by 
a case of spontaneously regressing sarcoma following post-operative bacterial infection, Dr. 
Coley attempted to cure his own patients, with limited success, using different bacterial toxins to 
induce tumor regression.1  This early work hinted that manipulating the immune system could 
have profound effects on cancer progression.   
The importance of the immune system in cancer has also been highlighted by clinical 
observations that immunocompromised patients have differing incidences of certain 
malignancies.2,3  Following these observations, many studies have shown that malignant tissue is 
often infiltrated by diverse classes of immune cells, including innate immune cells like 
macrophages and neutrophils as well as adaptive immune cells like B lymphocytes and T 
lymphocytes.  Importantly, recent studies have shown that T cell infiltration is associated with a 
better prognosis for several cancers, whereas myeloid cell infiltration tends to be associated with 
poor prognosis.4-7  As will be discussed below, the most convincing data regarding the 
importance of the immune system in the control of human cancer comes from clinical trials using 
therapies designed to specifically modulate antitumor T cell responses. 
Substantial preclinical data using animal models has shown the immune system influences 
cancer progression.  Pioneering work in the 1950’s showed that inbred mice could be immunized 
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against a chemically-induced tumor and confer protection against challenge by the same 
tumor.8,9  Using several immunodeficient mouse lines, studies in the last two decades have 
elucidated some of the machinery involved in tumor rejection, showing that lymphocytes, 
perforin, and IFNγ are critically important for tumor immunity.10-12   
2. Melanoma 
2.1 Disease prevalence 
Melanoma is a malignancy of melanocytes.  It has been estimated that greater than 80,000 
patients in the United States will be diagnosed with melanoma and over 9,000 patients will die 
from this disease in 2017 alone.13  While most primary tumors occur in the skin, metastases often 
seed the lungs, liver, bones, and brain of patients, making treatment much more difficult.14  
Melanomas often arise from an accumulation of mutations induced by UV radiation from sun 
exposure.  Common mutations include activating mutations in BRAF (often BRAFV600E) and 
KIT.15,16  These oncogenes can be targeted with molecular inhibitors with some clinical 
success.17,18  Recently, antibodies targeting the T cell checkpoint molecules CTLA-4 and PD-1 
have been approved for metastatic melanoma, marking the beginning of a new era in the 
treatment of melanoma.19  These therapies will be discussed in greater detail below. 
2.2 Melanoma antigens 
Tumor antigens are peptides expressed in cancerous cells that can be recognized by the immune 
system.  They can be divided into two broad categories: the first category includes antigens 
shared by both malignant cells and healthy tissue, and the second consists of antigens produced 
as a result of nonsynonymous mutations in the cancer genome.  Shared tumor antigens are 
peptides found in both malignant and healthy tissues that are either overexpressed in transformed 
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cells or have limited expression in normal cells such as proteins expressed during embryonic 
development that may be re-expressed in tumor tissue.20  Melanoma differentiation antigens 
(MDA) like gp100, tyrosinase, Trp1, and Trp2 are proteins involved in melanosome function 
whose expression are restricted to normal melanocytes and melanoma.  In some patients with 
melanoma, T cell responses to MDAs develop spontaneously.20-22  Because of this observation, 
MDAs have been the target for many immunotherapies against melanoma, including vaccines 
and adoptive cell therapy.23-26 
A second class of tumor antigen has garnered much enthusiasm in recent years.  Neoepitopes are 
non-self-peptides formed as a result of nonsynonymous mutations within the cancer genome.27,28  
Because these epitopes are produced as a result of mutations occurring only in the malignant cell, 
they are theoretically highly specific to transformed tissue, making them intriguing targets for 
immunotherapy.  In theory, immune responses against neoepitopes should show limited side 
effects due to reduced targeting of healthy tissue.  Evidence for immune recognition of 
neoepitopes (or tumor-specific immune recognition) has existed for many years.28-31  However, 
until recently, technological limitations made it extremely difficult to definitely identify these 
mutated peptides.  With the great advances in sequencing technologies, significant effort has 
been expended to map and predict immunogenic neoepitopes.27,32-36  While predicting which 
mutations give rise to an immunogenic neoepitope remains a difficult task, clinic evidence for 
the importance neoepitopes in immunotherapy exists.  As will be discussed below, several 
studies have suggested that the profound clinical results seen in some patients following 
checkpoint blockade therapy or adoptive cell therapy may rely on enhancing the endogenous T 
cell response to neoepitopes.37-42   
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3. Immunotherapy of Melanoma 
3.1 Vaccines 
Several decades have passed since the identification of T cell epitopes in melanoma patients.  
This discovery energized scientists and clinicians to attempt to generate or boost the T cell 
responses against melanoma using vaccination.  Early work focused on targeting MDAs like 
gp100 and MART-1 in peptide vaccine formulations.24  While it was possible to detect MDA-
reactive T cells following vaccination, clinical responses were modest at best.43-45  These studies 
and our own preclinical data highlight the difficulty in generating effective antitumor immune 
responses against shared antigens.  Several preclinical studies show that vaccination against 
neoepitopes is possible and can delay tumor growth.34-36  Two clinical trials are currently 
underway to determine if vaccination against neoepitopes might generate more dramatic clinical 
responses in patients with melanoma (NCT01970358; NCT02035956).   
3.2  Adoptive cell therapy 
Pioneering work by Dr. Steven Rosenberg at the NCI has developed a form of immunotherapy 
involving the transfer of large numbers of tumor-reactive lymphocytes into patients.26,46  This 
modality of immunotherapy consists of two major methods.  The first to be developed involves 
culturing tumor infiltrating lymphocytes (TIL) obtained directly from tumor tissue to greatly 
expand the TILs.  The patient then receives a lymphodepleting regimen, consisting of 
combination chemotherapy, before transfer of large numbers of cultured TIL to aid in the 
expansion and persistence of transferred cells, which has been correlated with improved 
responses.47,48  Patients then receive several doses of system IL-2 to aid the expansion of 
transferred TIL.46,49  This therapy has shown up to 55% objective response rate in patients with 
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metastatic melanoma, illustrating the potential power of this treatment modality and again 
providing perhaps the most convincing clinical data that T cells can control tumor growth.49  
Subsequent studies have shown that adoptively transferred TIL can recognize neoepitopes.37,38 
This recognition likely explains the success of this form of immunotherapy because transfer of 
autologous T cells enriched for reactivity to MDAs caused autoimmunity and had little clinical 
benefit, while transfer of autologous T cells enriched for reactivity against neoepitopes shows 
promising clinical activity.50,51 
A second class of adoptive cell therapy involves engineering receptors in cells to redirect T cell 
specificity prior to transfer into the patients.  Several studies have tried to redirect patient T cells 
to attack melanoma by transducing the expression of a traditional T cell receptor (TCR) 
recognizing different MDAs.  Morgan et al. engineered patient T cells to express a TCR 
recognizing MART-1.  Following lymphodepletion and cell transfer, two patients experienced 
tumor regression.52  In a larger study in which T cells were engineered to express a TCR 
recognizing MART-1 or gp100, objective tumor regression was seen in 30% and 19% of 
patients, respectively.  However, patients also experienced dermatitis, uveitis, and hearing loss 
due to destruction of normal melanocytes.25  These results make engineered T cells targeting 
shared antigens much less attractive. 
An exception to this pessimism is seen in results from engineered T cells targeting the B cell 
surface antigen, CD19.  Studies targeting this antigen have utilized T cells engineered to express 
a chimeric antigen receptor (CAR).  CARs are artificial receptors consisting of the extracellular 
variable regions of a tumor-antigen specific antibody and intracellular signaling domains 
consisting of CD3ζ and costimulatory signaling domains.  This artificial receptor allows 
recognition of tumor antigen without the need for MHC presentation.53  CAR T cells targeting 
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CD19 have shown impressive results in patients with B Cell Acute Lymphoblastic Leukemia.54-
57  Current research is focused on improving the persistence and trafficking of CAR T cells while 
increasing their resistance to tumor microenvironment immunosuppression.53  Extending these 
technologies to target other tumor types is also a major focus of research.  However, finding 
relevant targets on other solid tumors will likely be difficult because as discussed before, major 
toxicities are likely when targeting shared antigens.   
3.3  Checkpoint Inhibitors 
With the recent FDA approval of several T cell checkpoint inhibitors, cancer therapy has entered 
a new era in which immunotherapy joins surgery, radiation, and chemotherapy as pillars of 
clinical oncology.  Immune checkpoint inhibitors are thought to work by blocking the interaction 
of inhibitory receptors on the surface of antitumor T cells with their respective ligands, thereby 
“releasing the brake” on antitumor T cells and allowing tumor destruction.   
Ipilimumab, an antibody targeting CTLA-4, was the first checkpoint inhibitor approved by the 
FDA after it was shown to improve overall survival in patients with metastatic melanoma.58,59  
CTLA-4 (Cytotoxic T Lymphocyte Associated Protein 4) is an inhibitory receptor expressed on 
the surface of T cells during activation.  It recognizes CD80 and CD86 on antigen presenting 
cells during activation, and it binds with them with higher affinity than the costimulatory 
receptor CD28 which is also expressed on the surface of T cells.60-62  CTLA-4 is therefore 
believed to limit the availability of CD80 and CD86 for CD28 costimulation during T cell 
activation.  Based on these observations, Leach et al. first showed the antitumor effects of 
CTLA-4 blockade in murine tumor models.63  It has since been discovered that CTLA-4 is also 
highly expressed on Foxp3+ regulatory T cells (Treg), and CTLA-4 signaling in Tregs can 
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increase their immunosuppressive effects.64  Subsequent studies have suggested that the clinical 
responses to CTLA-4 blockade are likely due to effects on both effector T cells and Tregs.65   
Shortly after the approval of ipilimumab, several antibodies targeting the PD-1/PD-L1 axis were 
also shown to significantly improve survival in patients with metastatic melanoma.66,67  PD-1 
(Programmed Cell Death Protein 1) is a surface receptor expressed by activated T cells, B cells, 
and some myeloid cells.68  PD-1 signaling dampens T cell proliferation and cytokine secretion 
primarily by reducing costimulatory signals through CD28.69,70  PD-1 has two major ligands, 
PD-L1 and PD-L2.  PD-L1 is expressed on a diverse set of cells including immune cells, 
endothelial cells, and malignant cells.71  PD-L2 expression, on the other hand, is limited mainly 
to myeloid cells.71  PD-L1 is upregulated in tumor tissue in response to T cell infiltration and 
IFNγ release, and the interaction between PD-1 and PD-L1 protects tumors from T cell-mediated 
destruction.72-74   
Unfortunately, not all patients respond checkpoint inhibitors.  In the case of PD-1 blockade, 
several studies have suggested that PD-L1 expression within the tumor can be predictive of 
clinical responses.75-77  In responders, PD-L1 is likely expressed as a consequence of T cell 
infiltration while also negatively regulating T cells within the tumor microenvironment.77  If so, 
what are the target antigens for these T cells?  Several studies have shown that clinical response 
to PD-1 or CTLA-4 blockade correlates with mutational burden and predicted neoepitope 
frequency.39-42,78,79  Thus, it is likely that tumor regression following checkpoint inhibition 
requires a T cell response against neoepitopes in most cases. 
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4. T Cell Response to Cytomegalovirus 
4.1 Cytomegalovirus is a prevalent herpesvirus 
Cytomegalovirus (CMV) is a DNA, enveloped β-herpes virus that infects more than 60% of 
Americans over the age of 50.80  Like other members of the herpes virus family, CMV is never 
cleared from the infected host.  Following an asymptomatic acute infection, CMV enters a state 
of latency in several organs including lungs, liver, spleen, and brain.81  During this period, few 
infectious viral particles are produced yet viral transcription is detectable.82,83  For most 
immunocompetent adults, CMV never produces symptomatic disease, instead relying on periods 
of asymptomatic reactivation and shedding for spread to new hosts.  However, CMV can 
produce severe pathology in neonates and immunocompromised adults due to unrestrained viral 
spread.84-88  More recent work has also suggested that CMV can undergo subclinical reactivation 
in critically ill immunocompetent hosts, and this reactivation is associated with worse outcomes.  
However, the exact mechanism for this association has not been elucidated.89-93 
4.2 T cell memory inflation 
The immune response to CMV has become an increasingly popular research topic in recent 
years.  Given the persistent nature of the virus, the host immune system answers the infection 
with a unique T cell response termed “memory inflation” in which a high frequency of virus-
specific lymphocytes persists in blood, lymphoid tissue, and non-lymphoid tissue over the 
lifetime of the host.  This phenomenon has been best characterized with CD8+ T cells in humans, 
non-human primates, and rodents (Figure 1-1).94-96  In healthy CMV-seropositive humans, CMV-
specific CD8+ T cells can represent up to 20-30% of circulating CD8+ T cells, and these cells 
display an effector memory or terminally differentiated effector phenotype characterized as 
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CD45RA-CCR7- or CD45RA+CCR7-, respectively.95-97  A similar accumulation of CMV-
specific CD4+ T cells seems to occur in humans albeit at lower frequencies.95,97,98  It has been 
postulated that having such a large proportion of the immune system responding to CMV may 
cause premature aging of the immune system and limit the repertoire of non-CMV-specific T 
cells.99-101  More work is needed to fully elucidate the role of CMV in aging. 
Murine Cytomegalovirus (MCMV) is a well-established model for human CMV infection with 
similar cellular tropisms and a similar host immune response.83,94,102  As such, it has been an 
invaluable tool for learning more about the inflationary response to CMV viruses.  Similar to 
human CMV, following an acute infection, MCMV spreads to several tissues including lungs, 
salivary glands, spleen, and liver, among others.102,103  Within two weeks, viral load decreases 
significantly in most tissues except salivary gland where the viral load kinetics are delayed.103  
True latency defined by absence of detectable viral transcripts is established within 4 months of 
infection in Balb/c mice and probably earlier in C57BL/6 mice which are more resistant to 
MCMV.91,104   
Like human CMV, MCMV elicits an inflationary CD8+ T cell response characterized by large 
frequencies of virus-specific T cells that are maintained over the lifetime of the host.94,105,106  
These cells display an effector memory phenotype characterized by high expression of KLRG1 
and low expression of the IL-7 Receptor α, CD127.105  In contrast to other persistent viral 
infections that maintain high frequencies of virus-specific T cells, MCMV inflationary T cells do 
not become “exhausted”, as they display low expression of PD-1 and retain the capacity to 
produce IFNγ and TNFα following peptide stimulation.105,107  The reason for this is likely the 
rapid turnover of individual cells within inflationary cell populations.  While the frequency of 
inflationary T cells may remain relatively constant over time, individual cells within this 
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population do not persist over the course of the infection.105  The current model suggests that the 
majority of inflationary T cells displaying an effector memory phenotype are not long-lived but 
are constantly replaced by proliferating naïve cells or traditional memory cells that have recently 
encountered viral antigen.94,105  A recent study by Quinn et al. suggests that within the 
inflationary pool, a long-lived population of KLRG1-CD27+ “memory-like” cells can be 
repeatedly stimulated to produce progeny with an effector memory phenotype.108  Thus, it is 
likely that the vast majority of inflationary T cells are short-lived cells constantly replaced by 
proliferating memory or naïve cells.  Because CMV is only sporadically transcriptionally active 
during latency, inflationary CMV-specific T cells likely only rarely encounter viral antigen.94,109  
Sporadic stimulation by antigen may explain why MCMV inflationary T cells do not become 
exhausted while T cells seen in other chronic infections do. 
Importantly, not all MCMV-specific T cells undergo inflationary expansion.  In C57BL/6 mice, 
CD8+ T cells recognizing the peptides m38, m139, and ie3 undergo inflationary 
expansion.94,105,106  Other CD8+ T cells recognizing the peptides m45 and m57 show more 
traditional CD8+ T cell kinetics characterized by rapid expansion in the first week of infection 
followed by dramatic contraction and maintenance of a low-frequency of central memory cells in 
lymphoid tissues.94,105,106  The exact mechanisms determining whether an epitope generates an 
inflationary or non-inflationary T cell response are still incomplete.  However, several studies 
have attempted to address this issue.  It is now clear that the promoter regulating the expression 
of the peptide is crucial for determining what kind of T cell response will form.  Dekhtiarenko et 
al. showed that a recombinant MCMV engineered to express an HSV-1 epitope fused to ie2, a 
peptide that is expressed early during MCMV reactivation, generated an inflationary T cell 
response to the HSV-1 epitope, whereas a virus engineered with the HSV-1 epitope fused to the 
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m45 peptide, which elicits a traditional T cell response, generated a non-inflationary T cell 
response.110  This data supports the model that inflationary T cells are stimulated by viral 
peptides that are expressed in latency or early during reactivation.  Thus, a promoter expressed 
during latency or early reactivation is likely required to elicit an inflationary T cell response. 
4.3 Cytomegalovirus as a vaccine vector 
Historically, vaccines have largely focused on generating long-lived humoral immunity by 
exposing vaccinated individuals to short bursts of target peptide along with adjuvant.  While 
neutralizing antibodies may be effective against some extracellular pathogens, they are clearly 
ineffective for other microbes that establish intracellular reservoirs.  For this reason, vaccine 
formulations aimed at generating long-lived T cell responses have been a major focus of 
research.111   
Cytomegalovirus has several properties making it an attractive vaccine platform.  1) As 
discussed above, CMV generates a lifelong T cell response characterized by persistence of a 
large population of functional T cells in both lymphoid and non-lymphoid tissue.  Thus, 
engineering a CMV vector generating a similar T cell response against another antigen of interest 
could potentially provide lifelong immunity without the need for multiple vaccinations.  2) CMV 
utilizes many immunoevasive mechanisms to avoid elimination from infected hosts.  These 
mechanisms also prevent neutralizing immunity, allowing reinfection of individuals with 
multiple strains of CMV.112-115  Thus, unlike vaccine vectors against other microbes, CMV-based 
vaccines could be used in CMV-seronegative and –seropositive patients alike, and vaccination 
with one CMV-based vaccine should not diminish the response generated by a second CMV-
based vaccine.  3) Another critical and intriguing characteristic of CMV-based vaccines is that a 
fully functional virus is not required to generate inflationary T cell responses.  As discussed 
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above, CMV is a human pathogen that causes severe disease in immunocompromised patients 
and may impact critically-ill immunocompetent patients as well.84-87,89,90  Vaccinating patients 
with a live virus therefore increases risks for some patients.  However, a critical study in mice 
showed that a recombinant MCMV virus incapable of spreading from cell-to-cell after the initial 
infection still produced an inflationary T cell response.116,117  Thus, CMV-based vaccines can be 
engineered to dramatically reduce the chances of CMV pathology due to viral reactivation, while 
also maintaining an effective inflationary T cell response.  These properties make CMV an 
attractive and relatively safe platform for vaccine development. 
Several groups have generated recombinant Cytomegalovirus-based vaccines against different 
infectious agents.  Tsuda et al. showed that a recombinant MCMV expressing an epitope from 
Ebolavirus could generate an inflationary CD8+ T cell response against the Ebola epitope and 
vaccination with this recombinant MCMV protected mice from challenge with Ebolavirus.118,119  
Similarly, other groups have shown that MCMV-based vaccines for Influenza and Respiratory 
Syncytial Virus can produce inflationary T cell responses and protect mice from challenge with 
these pathogens.120,121  Another study showed that an MCMV-based vaccine can protect mice 
against challenge with Mycobacterium Tuberculosis even though the vaccine generates a modest 
inflationary T cell response.122  Perhaps the most promising studies using CMV-based vaccines 
have shown that recombinant rhesus Cytomegalovirus expressing epitopes from Simian 
Immunodeficiency Virus (SIV) can elicit impressive protection against challenge with SIV.123,124  
In this case, the efficacy of the vaccine may rely on non-traditional CD8+ T cell responses that 
recognize both MHC-I and MHC-II restricted epitopes.125  Future studies will undoubtedly 
continue to develop CMV-based vaccines for infectious disease, particularly for HIV. 
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Given the properties of CMV-based vaccines described above, our group and others have been 
interesting in developing CMV-based vaccines against cancer.  The first study to test this idea 
was published by Klyushnenkova et al. in 2012.  In this study, mice vaccinated with a MCMV 
vector expressing an epitope from Prostate Specific Antigen (PSA) developed inflationary CD8+ 
T cell responses against PSA and showed delayed tumor growth in a model of prostate cancer.126  
Interestingly, the same vector expressing full-length PSA induced a weaker PSA-specific CD8+ T 
cell response which correlated with reduced tumor control compared to the vector expressing the 
CD8 epitope alone.  The authors speculate that the full length peptide may generate regulatory T 
cells through CD4 epitope expression; however, the exact reason for the discordant results is 
unknown.126  Another study by Xu et al. in 2013 generated a CMV-based vaccine for melanoma.  
In this study, a MCMV vector expressing the melanoma differentiation antigen, Trp2, did not 
elicit a detectable T cell response to Trp2.  Instead, mice vaccinated with this vector developed 
an antibody response to Trp2 which had modest effects on B16 melanoma tumor growth.127  A 
more recent study by the same group showed that a MCMV vector expressing a modified CD8 
epitope for the melanoma antigen, gp100, could elicit a gp100-reactive CD8+ T cell response, but 
this had only modest effects on tumor growth following intraperitoneal vaccination.  
Intratumoral vaccination, however, completely eradicated some B16 melanomas, but 
surprisingly, this effect was less dependent on viral expression of the tumor antigen, as MCMV 
expressing gp100 had similar effects as wild type MCMV injected directly into the tumor.128 
Our lab has also previously generated a MCMV-based vaccine for melanoma.  This MCMV 
vector (MCMVgp100KGP) contains the full-length gp100 peptide sequence which has been 
mutated at 3 amino acids within the well-characterized CD8+ T cell epitope gp10025-33 
(EGSRNQDWL=>KGPRNQDWL).  MCMVgp100KGP induces a CD8+ T cell response against 
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the native gp10025-33 epitope in vaccinated mice and significantly delays tumor growth in a lung 
metastatic model of B16F10 melanoma.129,130  The major focus of my thesis has been to explore 
methods for improving the antitumor efficacy of MCMV-based vaccines by creating novel 
vectors expressing multiple tumor antigens and combining MCMV-based vaccines with other 
immunotherapies targeting immunosuppressive pathways found in the tumor microenvironment 
(Figure 1-2).   
Figures: 
 
Figure 1-1: Inflationary CD8+ T cells recognizing MCMV antigens accumulate over the 
lifetime of the host.  C57BL/6 mice were infected with 105 MCMV Smith strain.  CD8+ T cells 
recognizing the inflationary epitope, m38, are maintained at high frequencies over the lifetime of 
the host, while T cells recognizing a non-inflationary epitope, m45, display a traditional T cell 
response.  Frequencies of epitope-specific T cells were determined by staining peripheral blood 
leukocytes with m38- and m45-peptide tetramers. 
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Figure 1-2: Rationale for combining CMV-based tumor vaccines with other 
immunotherapies.  1) CMV-based vaccines allow persistent presentation of tumor antigen in 
peripheral tissues to allow continuous stimulation of tumor-specific T cells.  2) Activated tumor-
specific T cells migrate into tumor microenvironment.  3) Tumors utilize many strategies to limit 
antitumor T cell activity in the tumor microenvironment including accumulation of 
immunosuppressive immune cells, expression of inhibitory ligands, local tryptophan depletion, 
and tissue hypoxia, among others.  Targeting these immunosuppressive pathways may enhance 
the efficacy of CMV-based vaccines. 
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Chapter 2: Materials and Methods 
2.1 Mice 
Female C57BL/6 mice (6-8 weeks old) were purchased from Charles River (Frederick, MD).  All 
mice used in these studies were between 6 and 12 weeks of age at the start of the experiment.  
Breeding pairs of PMEL mice (B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J) were purchased from the 
Jackson Laboratory (Bar Harbor, ME) and bred in house.  Mice were housed at the University of 
Connecticut Health Center in a pathogen-free facility, and all experiments were performed with 
approval by the University of Connecticut Health Center Institutional Animal Care and Use 
Committee. 
2.2 Cell Lines and Viruses 
B16F10 and B16ova were provided by Dr. Leo Lefrançois (University of Connecticut Health 
Center).  B16F10-RFP was purchased from AntiCancer, Inc. (San Diego, CA).  B16F10 cells 
were cultured in DMEM media (Life Technologies) supplemented with 10% fetal bovine serum 
(Life Technologies), 1mM sodium pyruvate (Life Technologies), 1% non-essential amino acids 
(Life Technologies), and 1% Penicillin/Streptomycin (Life Technologies).  B16ova cells were 
cultured in B16F10 culture media supplemented with 500 µg/mL G418 (Life Technologies).  
B16F10-RFP were cultured according to supplier’s instructions in RPMI 1640 media (Life 
Technologies) supplemented with 10% fetal bovine serum, 2mM L-Glutamine (Life 
Technologies), 1% Penicillin/Streptomycin, and 400µg/mL G418.  Mouse embryonic fibroblasts 
(MEFs) were cultured in DMEM media supplemented with 5% fetal bovine serum, 1% non-
essential amino acids, 1% sodium pyruvate, 2mM L-Glutamine, and 1% Penicillin/Streptomycin.  
M2-10B4 (a kind gift from Dr. Christopher Snyder; Thomas Jefferson University) were cultured 
 17 
 
in RPMI-1640 media supplemented with 10% fetal bovine serum, 2mM L-Glutamine, and 1% 
Penicillin/Streptomycin. 
MCMVova was provided by Dr. Carol Wu (University of Connecticut Health Center).  Wild 
type MCMV, MCMVgp100, and MCMVgp100KGP were previously generated in the lab by Dr. 
Zhijuan Qiu using the MCMV BAC pSM3fr-MCK-2fl provided by Dr. Barbara Adler (Ludwig-
Maximilians-University Munich, Germany).129  Briefly, the full-length murine gp100 coding 
sequence or the altered sequence (gp100KGP) was inserted into the MCMV ie2 locus under the 
control of the HCMV ie1 promoter.129  Previously generated viruses (WT MCMV, 
MCMVgp100, and MCMVgp100KGP) were expanded using murine embryonic fibroblasts or 
the bone marrow stromal cell line, M2-10B4, as previously described.131 
2.3 Generating MCMVgp100KGP-Trp2 and MCMVgp100KGP-Trp2-2M 
Recombinant MCMV viruses expressing gp100KGP and the melanoma antigen Trp2 were 
generated by BAC recombineering using galK positive/negative selection.132  The MCMV BAC 
pSM3fr-MCK-2fl was provided by Dr. Barbara Adler (Ludwig-Maximilians-University Munich, 
Germany).  pSM3fr-MCK-2fl-gp100KGP was generated as previously described.129  To generate 
pSM3fr-MCK-2fl-gp100KGP-Trp2 and pSM3fr-MCK-2fl-gp100KGP-Trp2-2M, a two-step 
galK selection in the SW102 bacterial strain (provided by Biological Resources Branch, National 
Cancer Institute Preclinical Repository) was used to insert the Trp2 or Trp2-2M coding sequence 
along with an Internal Ribosomal Entry Sequence (IRES) just downstream of the gp100KGP 
coding sequence.  To begin, a galK targeting cassette was generated by amplifying pgalK 
(provided by Biological Resources Branch, National Cancer Institute Preclinical Repository) 
using primers galK-targeting-F 5’-ACAGCCCGCTCCTCAGTGGACAGCAGGT CTGAGTCG 
ACGGTACCGCGGGCCCTGTTGACAATTAATCATCGGCA-3’ and galK-targeting-R 5’-
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AAAGCAAGTAAAACCTCTACAAATGTGGTATGGCTGATTATGATCA GTTATCA 
GCACTGTCCTGCTCCTT-3’.  Underlined sequences are homologous to pgalK and non-
underlined sequences are homologous to pSM3fr-MCK-2fl-gp100KGP.  A first recombineering 
step using galK positive selection was used to generate pSM3fr-MCK-2fl-gp100KGP-galK.  The 
Trp2 coding sequence was amplified from a plasmid containing the Trp2 gene (Origene) with 
primers containing the restriction sites for NcoI and SalI, Trp2-F 5’- 
CCATGGGCCACCATGGGCCTTGTGGGATGGG-3’ and Trp2-R 5’- GTCGACCTAGGCT 
TCCTCCGTGTATC-3’.  Sequences in italics correspond to restriction sites for NcoI and SalI, 
respectively, and underlined sequences are homologous to Trp2 gene encoding plasmid.  Trp2 
was cloned into pMigR just downstream of the EMCV IRES sequence generating pMigR-Trp2.  
To produce pMigR-Trp2-2M, site-directed mutagenesis was performed on pMigR-Trp2-2M 
using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) and primers 
Trp2-2M-F 5’- ACACAAAAAAGTCATACATGCTGCAGTTGGCGATCTG-3’ and Trp2-2M-
R 5’- CAGATCGCCAACTGCAGCATGTATGACTTTTTTGTGT-3’.  Mutation of the Trp2 
CD8 T cell epitope was confirmed by sequencing.  Finally, to generate pSM3fr-MCK-2fl-
gp100KGP-Trp2 and pSM3fr-MCK-2fl-gp100KGP-Trp2-2M, a second recombineering step 
using galK negative selection was performed to replace the galK sequence with our target 
construct.  To do this, targeting cassettes containing IRES-Trp2 or IRES-Trp2-2M were 
amplified using primers IRES-trp2-targeting-F 5’- 
ACAGCCCGCTCCTCAGTGGACAGCAGGTCTGAGTCGACGGTACC 
GCGGGCCTCTCGAGGTTAACGAATTCCGCCCCCCCC-3’ and IRES-trp2-targeting-R 5’- 
AAAGCAAGTAAAACCTCTACAAATGTGGTATGGCTGATTATGATCAGTTACTAGGCT
TCCTCCGTGTATCTCTTGCTGCT-3’.  Underlined sequences are homologous to pSM3fr-
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MCK-2fl-gp100KGP and the non-underlined sequences are homologous for pMigR-Trp2.  To 
increase the efficiency of recombineering, the homologous arms of the targeting cassettes IRES-
Trp2 and IRES-Trp2-2M were extended using a second amplification step containing 5’ and 3’ 
overlapping homologous arms.  These overlapping homologous arms were generated by 
amplifying segments from pSM3fr-MCK-2fl-gp100KGP using the primers homologyarm1-F 5’- 
TTGAGCTGACTGTGTCCTGC-3’ and homologyarm1-R 5’- CAGACCTGCTGTCCACT 
GAG-3’ for one reaction and homologyarm2-F 5’- AGCCATACCACATTTGTAGAGGT-3’ 
and homologyarm2-R 5’- GGGCTTCTAATTACGTGACGC-3’ for the second reaction.  The 
products of these two PCR reactions were then used to amplify the targeting cassettes IRES-Trp2 
or IRES-Trp2-2M, generating the targeting cassettes with roughly 400-500bp 5’ and 3’ 
homology to pSM3fr-MCK-2fl-gp100KGP.  This extended targeting construct was then used in 
the final recombineering step to replace the galK construct within pSM3fr-MCK-2fl-gp100KGP-
galK, generating pSM3fr-MCK-2fl-gp100KGP-Trp2 and pSM3fr-MCK-2fl-gp100KGP-Trp2-
2M.  Correct insertion was verified by restriction enzyme digest and by sequencing of the target 
insertion sequence.  To produce live virus, MEFs were transfected with pSM3fr-MCK-2fl-
gp100KGP-Trp2 or pSM3fr-MCK-2fl-gp100KGP-Trp2-2M using X-tremeGENE 9 DNA 
Transfection Reagent (Roche).  Each recombinant virus was passaged in vitro at least three times 
before use in vivo. 
2.4 Western blot 
MEFs were infected with WT MCMV, MCMVgp100KGP-Trp2, or MCMVgp100KGP-Trp2-
2M.  Two days later, cells were harvested and lysed RIPA lysis buffer.  Uninfected MEFs and 
B16F10 cells were also harvested as controls.  Total protein content was quantified using Pierce 
BCA Protein Assay Kit (ThermoScientific).  15µg protein was mixed with 4X Laemmli Sample 
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Buffer (Bio-Rad), boiled for 5 minutes, and run on 10% Mini-PROTEAN TGX Precast Gel (Bio-
Rad).  Protein was transferred to nitrocellulose membrane overnight by wet electrotransfer.  The 
membrane was blocked for 1 hour in 5% Milk in TBS-T (0.1% Tween 20 in Tris-buffered saline 
(Bio-Rad)) followed by overnight incubation with anti-Trp2 (Abcam ab740473).  After washing 
with TBS-T, membrane was incubated with anti-Rabbit-HRP for 1 hour.  Secondary was washed 
away with TBS-T and bands were detected by chemiluminescence (ThermoScientific).  The 
same membrane was then stripped with Restore Western Blot Stripping Buffer 
(ThermoScientific) and reprobed with anti-gp100 (Abcam ab137078) and anti-β tubulin (Cell 
Signaling 2128). 
2.5 Ex vivo peptide stimulation 
Splenocytes were stimulated with 1µg/mL murine gp100 peptide or 1µg/mL PMA/Ionomysin 
(BD Biosciences) for 5 hours at 37°C in the presence of Brefeldin A (BD Biosciences) followed 
by intracellular staining for IFNγ. 
2.6 In vitro culture of PMEL cells 
Splenocytes from PMEL mice were cultured in RPMI containing 10% fetal bovine serum, 1% 
sodium pyruvate, 2% HEPES, 1% L-Glutamine, 100µM non-essential amino acids, 0.05mM 2-
mercaptoethanol, and 1% penicillin/streptomycin supplemented with 1µg/mL human gp100 
peptide and 30IU/mL recombinant human IL-2.  Cells were split after daily after two days and 
harvested on day 7 of culture for adoptive transfer in tumor-bearing mice. 
2.7 B16-specific ELISA 
96-well plates were coated overnight with B16F10 lysate.  After blocking with 5% BSA for 1 
hour, dilutions of sera from unvaccinated mice or mice vaccinated with recombinant MCMV 
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were added to individual wells for 2 hours.  Wells were then incubated with HRP-conjugated 
anti-mouse IgG for 1 hour.  3,3’,5,5’-tetramethylbenzidine was then added to each well and plate 
was read at 492 nm in colorimetric plate reader. 
2.8 Tumor challenge experiments 
Female C57Bl/6 mice received an intradermal or intravenous injection of 105 B16F10 or 
B16RFP or 3x105 B16ova.  Mice were then vaccinated with WT or recombinant MCMV 
depending on the experiment.  For intravenous tumor inoculation studies, mice were euthanized 
2-3 weeks after challenge, lungs excised, and tumor nodules were counted manually under a 
dissecting microscope.  In some experiments, splenocytes corresponding to 105 CD8+ PMEL 
cells from naïve PMEL mice or 105 CD8+ OT-I cells from OT-I/Rag- mice were transferred into 
naïve WT tumor-bearing mice two hours prior to vaccination with WT or recombinant MCMV.  
Intradermal tumor growth was monitored every 2-3 days by measuring length and width of the 
tumor using calipers and multiplying to calculate surface area.  Mice were euthanized when 
tumors reached >100 mm2 or ulcerated.  In some experiments, tumor-bearing mice also received 
i.p. injections of anti-PD1 antibody (RMP1-14; BioXcell), anti-Qa-1b (4C2.4A7.5H11; 
BioXcell), anti-CTLA4 (UC10-4F10-11; BioXcell) or isotype controls.  For IDO inhibition 
experiments, the IDO inhibitor 1-methyl-D-tryptophan (1-MT; Sigma) was dissolved in 1M 
NaOH, diluted to 2mg/mL in drinking water, and pH was adjusted to 9 using 1M HCl.  Control 
mice received water adjusted to pH 9 without 1-MT.  Water was replaced every 4-5 days. 
2.9 Flow cytometry 
Tumor tissue was mechanically dissociated and digested in 0.7mg/mL Collagenase D (Roche) 
and 3mg/mL DNase I (Roche) for 30-45 minutes to obtain single cell suspension.  For 
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experiments looking at tumor infiltrating leukocytes, TIL were isolated using Percoll gradient 
prior to staining.  For experiments looking at B16RFP+ tumor cells, cells were stained 
immediately after digestion for 20 minutes.  Cells were blocked with anti-CD16/32 (clone 93; 
Biolegend) prior to surface staining.  For intracellular staining, cells were fixed and 
permeabilized using Cytofix/Cytoperm (BD Biosciences) or FoxP3 Staining Kit (eBioscience) 
prior to staining for intracellular antigens.  Antibodies against the following antigens were used: 
CD11a (clone M17/4; ThermoFisher), CD8a (clone 53-6.7; BD Biosciences or Biolegend or 
eBioscience), CD45 (clone 30-F11; Invitrogen or eBioscience), CD45.1 (clone A20; Biolegend), 
CD3 (clone eBio500A2; eBioscience), CD45.2 (clone 104; eBioscience), CD90.1 (clone OX-7; 
BD Biosciences), CD127 (clone A7R34; eBioscience or clone SB/199; Biolegend), KLRG1 
(clone 2F1/KLRG1; Biolegend or eBioscience), CD4 (clone RM4-5; eBioscience or clone 
GK1.5; Biolegend), PD-1 (clone RMP1-30; eBioscience), CTLA-4 (clone UC10-4F10-11; BD 
Biosciences), NKG2A/C/E (clone 20d5; eBioscience), LAG3 (clone C9B7W; Biolegend), 2B4 
(clone m2B4(B6)458.1; Biolegend), CD44 (clone IM7; eBioscience or Biolegend or BD 
Biosciences), Gr-1 (clone RB6-8C5; Biolegend), Ly6C (clone HK1.4; Biolegend), Ly6G (clone 
1A8; Biolegend), CD11b (M1/70; eBioscience or Biolegend), CD11c (clone N418; Biolegend or 
eBioscience), CD169 (clone SER-4; eBioscience), CD115 (clone AFS98; eBioscience), CD64 
(clone X54-5/7.1; Biolegend), CCR2 (clone 475301; R&D Systems), CD80 (clone 16-10A1; 
Biolegend), MHCII (clone AF6-120.1), F4/80 (clone BM8; Biolegend), Qa-1b (clone 
6A8.6F10.1A6; Miltenyi Biotec), PD-L1 (10F.9G2; Biolegend), IDO1 (clone 2E2/IDO1; 
Biolegend), IFNγ (clone XMG1.2; Biolegend).   
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2.10 Confocal Imaging 
Tumor tissue was fixed and processed as previously described.133  Briefly, tumor tissue was fixed 
overnight in 0.05M phosphate buffer, 0.1M L-Lysine, 2mg/mL NaIO4, and 10mg/mL 
paraformaldehyde.  Tissue was dehydrated in 30% sucrose then frozen in OCT (Tissue-Tek).  
Tumors were cut into 20µm sections, blocked for two hours in 2% fetal bovine serum, 2% goat 
serum, and 0.5% Fc Block before staining for CD169 or F4/80 for 1 hour.  Images were acquired 
on Zeiss LSM 780 FCS/NLO (Carl Zeeis) or Zeiss LSM 880.  Images were analyzed using 
Imaris software (Bitplane, Inc.).  
2.11 Statistical analysis 
Statistical tests were performed in Prism (Graphpad).  For tumor growth experiments, tumor 
growth curves were compared using two-way repeated measures ANOVA.  For other 
experiments, a student t-test was used when comparing two groups, and a one-way ANOVA was 
used when comparing more than two groups.  A paired t-test was used to compare inhibitory 
receptor expression in blood and TIL from the same mouse.  Survival curves were analyzed 
using Logrank test in Prism. 
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Chapter 3: Generating MCMV-based Vectors Expressing Multiple 
Melanoma Antigens 
Abstract:  
Tumor antigen-specific CD8+ T lymphocytes can have potent antitumor effects, and evidence 
from studies using adoptive cell therapy have shown that sustained antitumor T cell responses 
confer the greatest clinical benefit.  Thus, generating robust and sustained T cell responses 
against tumor antigens is a critical focus of cancer immunotherapy research.  Cytomegalovirus is 
a herpesvirus that induces dramatic T cell responses against certain viral epitopes that are 
sustained at high frequencies over the lifetime of the host, a phenomenon termed “memory 
inflation”.  Impressively, vaccination with a recombinant murine Cytomegalovirus (MCMV) 
expressing an altered melanoma antigen induces a memory inflation T cell response to the 
antigen, and this protects mice against a metastatic model of melanoma.  In this study, we set out 
to engineer a novel recombinant MCMV expressing multiple tumor antigens with the aim of 
inducing memory inflation responses against multiple tumor antigens and improving the clinical 
efficacy of vaccination.  Herein, we show that altering the melanoma antigen Trp2 at one amino 
acid reduces the expression of the antigen by recombinant MCMV vectors.  We also show, in 
contrast to a previously published work, that MCMV expression of the native Trp2 protein does 
not delay tumor progression. 
Introduction:   
With the FDA approval of ipilimumab and nivolumab, cancer immunotherapy has entered 
mainstream clinical oncology.58,66  The potency of these therapies in some patients has shown the 
immense power of T cells in the fight against cancer.  Unfortunately, not all patients respond to 
this therapy.  T cell infiltration prior to therapy has been correlated with response to checkpoint 
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blockade and is a possible marker for stratifying potential responders prior to therapy.134  
However, not all patients exhibit this spontaneous antitumor T cell response and thus require 
other forms of therapy.   
Cancer vaccines have long been a focus of research within the tumor immunology field, but few 
vaccines have been effective in human trials.24,45  Our lab previously hypothesized that a 
persistent vaccine vector generating a prolonged antitumor T cell response would provide 
optimal tumor protection.129,130  Cytomegalovirus generates a unique CD8+ T cell response 
termed memory inflation, characterized by the maintenance of a high-frequency of activated, 
virus-specific T cells for the lifetime of the host.95  Previously, we showed that a recombinant 
murine Cytomegalovirus (MCMV) expressing an altered melanoma antigen, gp100KGP, could 
induce a memory inflation CD8+ T cell response against the native gp100 peptide, and 
vaccination with this recombinant virus delayed melanoma growth in a metastatic tumor 
model.129  Here, we engineer this same vaccine to express a second melanoma antigen, Trp2, and 
show that altering Trp2 at one amino acid reduces the expression of the protein in infected cells 
in vitro.  Surprisingly, vaccination with MCMV vectors expressing both gp100 and Trp2 
antigens did not significantly delay tumor growth compared to the MCMV vector expressing the 
altered gp100 alone.   
Results:  
Altering Trp2 limits expression by MCMV-based vectors 
Our group has previously generated recombinant MCMV vectors expressing the melanoma 
antigen, gp100, or a mutated form of the antigen, gp100KGP.  Highlighting the difficulty in 
vaccinating against self-peptides, we showed that mice immunized with MCMVgp100 did not 
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develop a CD8+ T cell response to gp100.  However, mice vaccinated with MCMVgp100KGP 
developed a memory inflation T cell response against the native gp100 peptide and were 
protected against tumor challenge in a metastatic model of B16F10 melanoma.129  We 
hypothesized that the addition of a second melanoma antigen could enhance the efficacy of our 
MCMV-based vaccine.  To this end, we sought to develop an MCMV vaccine expressing 
gp100KGP and a shared melanoma antigen, Trp2, or the mutated protein Trp2-2M.  Trp2-2M is 
mutated within the CD8+ T cell epitope Trp2180-188 (SVYDFFVWL=>SMYDFFVWL) and has 
been shown to generate cross-reactive T cell responses upon peptide vaccination.135  Given the 
importance of promoter activity in regulating memory inflation responses and given the effective 
antitumor responses seen with MCMVgp100KGP, we aimed to have Trp2 expression controlled 
by the same promoter as gp100KGP.  To do this, we inserted the native or altered murine Trp2 
coding sequence downstream of the gp100KGP coding sequence, separated by an Internal 
Ribosomal Entry Site (IRES).  This design enables the gp100KGP and the Trp2 genes to be 
transcribed into one mRNA transcript under the same promoter.  The IRES then allows 
translation of Trp2 independent of gp100KGP translation (Figure 3-1).136  Using a two-step galK 
positive/negative selection recombineering protocol, we generated two recombinant MCMV 
vectors.  MCMVgp100KGP-Trp2 was engineered to express the full-length murine Trp2 protein.  
MCMVgp100KGP-Trp2-2M was engineered to express a mutated Trp2 protein consisting of a 
single amino acid substitution within the CD8+ T cell epitope Trp2180-188 
(SVYDFFVWL=>SMYDFFVWL).   
We confirmed correct insertion of the IRES-Trp2 construct by sequencing and restriction 
mapping of the final bacterial artificial chromosomes (BAC) containing the recombinant MCMV 
genomes (Fig. 3-2).  We next sought to confirm expression of the melanoma antigens by 
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performing Western blots on lysates from infected murine embryonic fibroblasts (MEFs) (Figure 
3-3).  Trp2 and gp100KGP proteins were not detected in lysates from MEFs infected with WT 
MCMV, whereas gp100KGP expression was confirmed in lysates from cells infected with either 
recombinant virus.  Trp2 was easily detected in lysates from MEFs infected with 
MCMVgp100KGP-Trp2; however, there was minimal expression of Trp2-2M in infected MEFs, 
suggesting that the 2M mutation may have influenced Trp2 expression or protein stability.   
Trp2-specific T cells or antibodies are not detected following vaccination with recombinant 
MCMV vectors. 
Though it is difficult, several studies have shown it is possible to vaccinate mice with native 
Trp2 peptides and elicit a T cell response.137,138  Thus, we decided to test the ability of both 
recombinant MCMV viruses to induce CD8+ T cell responses to the native Trp2180-188 epitope.  
To this end, mice were vaccinated with 105 PFU WT MCMV, MCMVgp100KGP-Trp2, or 
MCMVgp100KGP-Trp2-2M.  Seven days after vaccination, splenocytes were stimulated with 
native gp10025-33 or native Trp2180-188 peptide for 5 hours and stained for IFNγ expression (Figure 
3-4).  None of the mice tested showed any reactivity to Trp2, again highlighting the difficulty of 
vaccinating against self-antigens.  Recently, Xu et al. constructed a MCMV vector expressing 
native Trp2 and also could not detect a Trp2-specific T cell response following vaccination.  
However, this group showed that vaccination with MCMV expressing Trp2 could generate an 
antibody response against Trp2 and slightly delay tumor growth.127  We therefore asked if 
MCMVgp100KGP-Trp2 or MCMVgp100KGP-Trp2-2M could also generate tumor-specific 
antibodies.  To test this, mice were again vaccinated with WT MCMV or recombinant MCMV 
and serum was collected 7 days later.  An ELISA assay targeting B16F10 tumor lysate was 
performed to detect B16-specific antibodies in vaccinated mice.  Serum from mice vaccinated 
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with WT MCMV showed an increase in reactivity compared to unvaccinated mice, likely a result 
of non-specific binding due to increased virus-specific IgG.  Serum from mice vaccinated with 
either recombinant virus showed similar B16-reactivity compared to WT MCMV, suggesting a 
lack of B16-specific IgG in these mice (Figure 3-5).  Thus, in contrast to the report by Xu et al., 
we were unable to detect an increase in B16-specific antibodies following vaccination with our 
recombinant viruses.   
Addition of Trp2 to MCMVgp100KGP does not enhance antitumor response 
While we did not detect adaptive immune responses to Trp2 in our previous assays, it was 
possible that the addition of Trp2 to MCMVgp100KGP would still yield beneficial antitumor 
effects as we were merely failing to detect these cellular responses in our specific assays.  We 
therefore performed a final set of experiments to determine if addition of Trp2 to 
MCMVgp100KGP had any effects on tumor growth.  Our previous study utilized a pulmonary 
metastatic model of melanoma in which mice were inoculated with B16F10 via the tail vein.  In 
this model, the melanoma cells seed the lungs, forming individual nodules which can be 
quantified.  To test the antitumor efficacy of our recombinant MCMV vectors, mice were 
inoculated with 105 B16F10 cells via tail vein injection.  Three days later, mice were vaccinated 
with 105 PFU MCMVgp100KGP, MCMVgp100KGP-Trp2, or MCMVgp100KGP-Trp2-2M.  
On day 22, mice were euthanized and pulmonary tumor nodules were counted (Figure 3-6A).  As 
shown in our previous study, vaccination with MCMVgp100KGP significantly decreased the 
tumor burden compared to untreated mice.  Similarly, vaccination with MCMVgp100KGP-Trp2 
or MCMVgp100KGP-Trp2-2M also significantly reduced the tumor burden compared to 
untreated mice.  However, tumor burden between vaccinated groups was not significantly 
different.  Lastly, we confirmed this result in a solid tumor model of melanoma in which B16F10 
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cells are injected intradermally.  In this model, a solid tumor mass forms in the skin which can be 
measured over time using calipers.  To try to increase the sensitivity of detecting differences 
between vaccinated groups, mice were vaccinated seven days prior to inoculation with B16 
tumors.  As in the metastatic model, vaccination with recombinant MCMV vectors delayed 
tumor growth when given prophylactically, but the addition of Trp2 did not enhance the efficacy 
of MCMVgp100KGP (Figure 3-6B). 
Discussion:  
The clinical development of vaccines targeting tumor antigens has been largely disappointing, 
reducing the optimism of many scientists for this approach to cancer therapy.24  However, the 
recent clinical successes of checkpoint inhibitors and adoptive cell therapy have shown the 
immense potential of antitumor T cell responses in fighting cancer.  Unfortunately, only a subset 
of patients respond to these therapies.  The effectiveness of these therapies likely depends on 
reinvigorating a pre-existing antitumor T cell response, meaning patients without this pre-
existing response are unlikely to respond.26,134  Therefore, novel methods for generating 
antitumor T cell responses in these patients is urgently needed.  Vaccination may be one of 
several effect means of producing these antitumor T cells, which can then be reinvigorated by 
checkpoint inhibition. 
With this in mind, our lab has investigated the preclinical utility of Cytomegalovirus-based 
vaccines for use in melanoma.  CMV infection elicits a unique CD8+ T cell response termed 
“memory inflation” which is characterized by the lifelong accumulation of activated virus-
specific cells in lymphoid as well as non-lymphoid tissues.95  Impressively, this memory 
inflation response is still observed following vaccination with a non-replicative viral vector, 
suggesting that vectors with limited virulence could still be used for vaccination.116  A vaccine 
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that could generate such a sustained T cell response against a target antigen could be highly 
effective in different settings.  Based on this idea, several groups have already tested 
recombinant MCMV viruses expressing epitopes from infectious agents like Influenza and 
Ebola.  In these studies, recombinant MCMV vectors elicit memory inflation CD8+ T cell 
responses against the target epitope and provide long-term protection against challenge.119,139  
This platform has also shown impressive preclinical results protecting rhesus macaques from 
highly pathogenic Simian Immunodeficiency Virus.123-125   
Our lab has previously applied this technology to create a novel MCMV-based vaccine 
expressing a modified melanoma antigen.  By mutating the self-antigen, gp100, within a known 
CD8+ T cell epitope, we were able to generate tumor-reactive T cells following vaccination that 
delayed tumor progression in a metastatic model of melanoma.  However, vaccination was not 
curative.129  Antigen loss is a potential escape mechanism for tumors under immune 
pressure.140,141  One way to minimize this escape mechanism is to target several antigens.  At the 
same time, polyclonal T cell responses are likely to be more effective in initial therapy as well.  
For these reasons, we sought to develop an MCMV-based vaccine expressing multiple 
melanoma antigens.   
In this study, we engineered our original MCMV melanoma vaccine (MCMVgp100KGP) to 
express a second melanoma antigen, Trp2, generating MCMVgp100KGP-Trp2.  Because it is 
difficult to vaccinate against self-proteins, we also developed a second virus expressing a 
modified Trp2, MCMVgp100KGP-Trp2-2M.  We hypothesized that this second modification 
would break self-tolerance and stimulate CD8+ T cells recognizing the Trp2180-188 epitope.
135  
While MCMVgp100KGP-Trp2 expressed high levels of gp100 and Trp2 in vitro, 
MCMVgp100KGP-Trp2-2M showed dramatically reduced expression of Trp2 at the protein 
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level.  The previous study using Trp2-2M vaccination utilized synthesized peptides and therefore 
did not investigate the effects of the 2M alteration on Trp2 protein expression.135  
MCMVgp100KGP-Trp2 and MCMVgp100KGP-Trp2-2M differ only at one amino acid within 
the protein coding region.  Thus, the regulatory units influences Trp2 transcription should remain 
functional between our two vectors.  It is more likely that the 2M modification influences either 
the translation or protein stability of Trp2.  These results highlight the potential problems in 
engineering altered epitopes into full-length proteins within expression vectors.  Engineering 
MCMV vectors expressing shorter peptides containing the epitopes of interest may improve 
epitope expression by reducing potential misfolding. 
Previous reports have shown that potent vaccine formulations can induce T cell responses 
against the native Trp2 peptide.137,138  We therefore decided to test our novel MCMV vectors in 
vivo.  We were unable to detect Trp2-specific CD8+ T cell responses following vaccination with 
either recombinant MCMV, illustrating the difficulty of vaccinating against self-proteins.  A 
previous study by Xu et al. similarly showed that a MCMV vector expressing the native Trp2 
was unable to induce a Trp2-specific T cell response following vaccination.  However, this study 
showed that vaccination with this vector slightly protected mice from tumor challenge by 
eliciting a Trp2-specific antibodies.127  We were unable to detect tumor-specific IgG following 
vaccination with MCMVgp100KGP-Trp2, and vaccination with either MCMVgp100KGP-Trp2 
or MCMVgp100KGP-Trp2-2M did not delay tumor growth compared to MCMVgp100KGP in a 
solid tumor or metastatic model of B16 melanoma.   
Our results stand in stark contrast to the study by Xu et al.  While neither study could generate 
Trp2-reactive T cells, we were unable to show any clinical benefit of Trp2 expression by an 
MCMV vector.  Several differences in our studies may explain this, the discrepancy.  First, the 
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regulatory elements controlling Trp2 were different in the two studies.  Xu et al. inserted the 
complete Trp2 coding sequence under the control of the human CMV major immediate early 
promoter and enhancer element, whereas, in our study, Trp2 transcription was controlled by the 
human CMV immediate early promoter without enhancer element.127  As described above, this 
ensured that in our study Trp2 was transcribed along with gp100KGP but was translated 
independent of gp100KGP through an internal ribosomal entry site.  Our data show that Trp2 
was successfully expressed in MEFs infected with MCMVgp100KGP-Trp2.  Nonetheless, the 
different regulatory elements involved in these two studies may influence the overall expression 
levels of Trp2 or the cell-specific expression of Trp2.  Differences in the overall expression of 
Trp2 or cell-specific expression may account for the differences observed in the two studies.  
Second, discrepancies in inoculation dose may contribute to our conflicting results.  Xu et al. 
vaccinated mice with 4x106 PFU MCMV-TRP2 which is a large inoculation dose for MCMV.127  
In our current study, mice were vaccinated with 105 PFU MCMVgp100KGP-Trp2.  Inoculation 
dose is known to impact the magnitude of antibody responses to MCMV antigens.142  While this 
lower dose was effective enough to delay tumor growth compared to untreated mice, we did not 
observe an IgG response to B16 or enhanced tumor protection compared to MCMVgp100KGP 
vaccination.   
In conclusion, in this study we set out to generate a recombinant MCMV vaccine expressing 
multiple melanoma antigens with the aim of generating multiple CD8+ T cell memory inflation 
responses against melanoma.  Herein, we show that the addition of native Trp2 to MCMV 
vectors is unable to break self-tolerance.  We were unable to detect T cell or antibody responses 
to Trp2 following vaccination with MCMVgp100KGP-Trp2.  In order to break self-tolerance 
against Trp2, we created a second MCMV vector expressing an altered Trp2.  However, 
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mutating Trp2 within the CD8+ T cell epitope Trp2180-188 significantly reduced the expression of 
the full-length protein in infected MEFs.  This study highlights the difficulty in vaccinating 
against shared tumor antigens.  Overcoming tolerance mechanisms is a problematic step in 
vaccinating against shared tumor antigens.  Future studies generating MCMV-based vaccines 
against tumor-specific epitopes, so called neo-epitopes, may enhance the efficacy of this vaccine 
platform in tumor immunotherapy. 
 
Figures: 
 
Figure 3-1: Expression of gp100KGP and Trp2 in MCMV vectors.  In order to keep Trp2 
under an effective memory inflation promoter, the Trp2 coding sequence was inserted 
downstream of gp100KGP before the poly(A) signal sequence and separated by an internal 
ribosomal entry site (IRES).  This allows gp100KGP and Trp2 transcription under the HCMV 
promoter into a single mRNA transcript.  Translation of Trp2 will occur independent of 
gp100KGP due to IRES recruitment of ribosomal machinery. 
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Figure 3-2: Restriction map of bacterial artificial chromosomes containing recombinant 
MCMV genomes.  BAC DNA encoding (A) MCMVgp100KGP, (B) MCMVgp100KGP-Trp2, 
or (C) MCMVgp100-Trp2-2M were purified and digested with HindIII for 4 hours and run on 
0.6% agarose gel for 24 hours.  Arrows show the expected changes in restriction bands following 
correct insertion of the IRES-Trp2 sequences. 
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Figure 3-3: Expression of melanoma antigens in fibroblasts infected with recombinant 
MCMV vectors.  Mouse embryonic fibroblasts (MEFs) were infected with recombinant MCMV 
vectors and lysates were analyzed by Western blot for protein expression of gp100 or Trp2.  
Lysates from 1) uninfected MEFs or 2) MEFs infected with WT MCMV showed no Trp2 or 
gp100 expression.  Lysates from 3) MEFs infected with MCMVgp100KGP-Trp2 showed clear 
bands for Trp2 and gp100, whereas lysates from 4) MEFs infected with MCMVgp100KGP-
Trp2-2M showed clear gp100 expression but minimal Trp2 expression.  Band specificity was 
confirmed using lysates from 5) B16F10 cells in culture. 
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Figure 3-4: Trp2-specific T cells are not detected following vaccination with recombinant 
MCMV vectors.  C57BL/6 mice were vaccinated with 105 PFU WT MCMV, 
MCMVgp100KGP, MCMVgp100KGP-Trp2, or MCMVgp100KGP-Trp2-2M i.p.  Seven days 
later, splenocytes were stimulated with m38 peptide (SSPPMFRV), gp100 peptide 
(EGSRNQDWL), Trp2 peptide (SVYDFFVWL), or PMA/I for 5 hours followed by intracellular 
cytokine staining.  Representative plots of 3 mice/group gated on CD45+CD3+CD8+ cells. 
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Figure 3-5: B16-specific antibodies are not detected following vaccination with 
recombinant MCMV vectors.  Serum was collected from mice that were previously vaccinated 
7 days prior with WT or recombinant MCMV.  Serum was serially diluted and incubated on 
plates pre-coated with B16 tumor lysate.  Plates were washed and stained with anti-mouse IgG-
HRP and incubated with TMB substrate prior to absorbance reading at 492 nm.  Serum from 
mice infected with WT MCMV or recombinant MCMV all showed increased absorption 
compared to serum from uninfected mice.  However, there was no significant difference in 
absorption between the different MCMV viruses. n=3 mice/group. 
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Figure 3-6: Addition of Trp2 to MCMVgp100KGP does not improve antitumor response 
vs. MCMVgp100KGP.  A) Mice were inoculated with 105 B16F10 via tail vein injection and 
vaccinated with 105 PFU recombinant MCMV three days later.  On Day 22, mice were sacrificed 
and lung tumor nodules were counted.  B) Mice were vaccinated with 105 PFU recombinant 
MCMV seven days prior to intradermal inoculation with 105 B16F10.  Tumor surface area was 
monitored over time using manual calipers.  n=7-8 mice/group for A) and 10-16 mice/group for 
B).  *p<0.05; **p<0.01. 
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Chapter 4: Combination Immunotherapy with MCMV-based 
Vaccines 
 
Abstract:  
With the exception of cancers associated with infectious agents, cancer vaccines have largely 
failed to impact disease progression.  The reasons for this are multifactorial, including 
suboptimal vaccine formulations, poor choice of target antigens, and a highly 
immunosuppressive tumor microenvironment.  In this study, we sought to increase the antitumor 
effects of a MCMV-based tumor vaccines by combining vaccination with other clinically-
relevant immunotherapies to enhance antitumor T cell responses within the tumor 
microenvironment.  Herein, we show that vaccination against a foreign tumor antigen can 
significantly delay tumor growth, and increasing the magnitude of this response through adoptive 
cell therapy cures mice with established tumors.  In contrast, vaccination against a shared tumor 
antigen is insufficient to delay growth of an established solid tumor.  Increasing the frequency of 
the antitumor T cell response through adoptive cell therapy significantly delays tumor growth, 
but vaccination also induces a robust counter-regulatory response marked by elevated PD-L1, 
Qa-1b, IDO expression, and recruitment of monocytic MDSCs.  Surprisingly, combination 
immunotherapy targeting several of these pathways did not impact survival of tumor-bearing 
mice.  Thus, this study highlights several potential barriers to effective tumor vaccination when 
targeting a shared tumor antigen and questions the accuracy of inhibitory pathway expression as 
a biomarker for responses to therapy. 
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Introduction: 
After decades of research, immunotherapy has finally joined surgery, radiotherapy, and 
chemotherapy as a standard treatment modality in clinical oncology.58,59,66  Unfortunately, these 
therapies seem to only work in patients who have a pre-existing immune response against the 
tumor, so called “inflamed” tumors, leaving little to no benefit for patients with “non-inflamed” 
tumors.143  Methods for converting “non-inflamed” tumor into “inflamed” ones are therefore 
needed to treat this subset of patients.  Vaccination is one potential method to generate an 
adaptive immune response against tumor cells.  Vaccination against tumor antigen has been a 
highly active area of research for decades that has yielded little clinical benefit as 
monotherapy.23,24  Reasons for the failures likely include choice target antigen and an 
immunosuppressive tumor microenvironment. 
Recent studies have suggested that the clinical responses seen in some patients following T cell 
checkpoint blockade or adoptive cell therapy are likely due to T cell responses against mutated 
tumor peptides termed neo-epitopes.39-42,78  Because they target non-self-peptides, high affinity 
neo-epitope-specific T cells do not get deleted during development in the thymus and are likely 
more effective in recognizing tumor cells.  Several groups have shown in preclinical models that 
it is possible to vaccinate against neo-epitopes and delay tumor growth, and clinical trials 
vaccinating patients against these antigens are currently underway (NCT01970358; 
NCT02035956).34-36   
The majority of tumor vaccines tested thus far have targeted shared antigens, i.e. antigens 
expressed by malignant and healthy tissue alike.24  Vaccination against this class of tumor 
antigen is difficult because high affinity T cells recognizing these antigens are largely deleted in 
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the thymus during development or are rendered unresponsive due to peripheral tolerance.  
However, it is possible to stimulate T cells against these antigens in certain cases.43   
Studies focused on a particular form of immunotherapy called adoptive cell therapy have 
suggested that prolonged T cell responses against tumor antigen inversely correlate with clinical 
progression.48  Our lab has previously hypothesized that a persistent vaccine stimulating lifelong 
T cell responses against tumor antigen would be an effective cancer immunotherapy.129,130  To 
test this, our group developed a vaccine based on Murine Cytomegalovirus targeting a shared 
melanoma antigen, gp100.  By mutating gp100 within a CD8+ T cell epitope, we were able to 
generate gp100-reactive T cells which delayed metastatic tumor progression following 
vaccination with MCMVgp100KGP.  However, vaccinated mice eventually succumb to 
disease.129  In the current study, we tested whether MCMV-based vaccines were effective in a 
solid tumor model (as opposed to the pulmonary metastatic model previously described).  In this 
way, we could examine the influence of an established tumor microenvironment on vaccine-
stimulated T cells.  Our results show that an MCMV-based vaccine targeting a model neo-
epitope is highly effective in treating melanoma-expressing the same neo-epitope, and combining 
this vaccination with adoptive cell therapy completely cures mice of disease.  We also show that 
prophylactic vaccination with MCMVgp100KGP delays tumor growth, but therapeutic 
vaccination has no effect on growth of established tumors.  Combining MCMVgp100KGP 
vaccination with adoptive cell therapy delays growth of established tumors and also induces 
several counter-regulatory mechanisms, including expression of inhibitory receptor ligands and 
recruitment of immunoregulatory cells.  Surprisingly, combination immunotherapy targeting 
several of these counter-regulatory pathways did not enhance the efficacy of vaccination.  This 
study highlights the difficulty in treating a highly immunosuppressive tumor with a vaccine 
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targeting a shared antigen and suggests that expression of immunosuppressive molecules within 
the tumor microenvironment does not always predict response to some modes of 
immunotherapy. 
Results: 
Therapeutic vaccination with MCMVgp100KGP does not delay tumor growth in an intradermal 
solid tumor model. 
Our group has previously shown that MCMVgp100KGP vaccination reduces tumor burden in a 
pulmonary metastatic model of B16 melanoma.129  In order to more closely examine the impact 
of the tumor microenvironment on vaccine efficacy, we switched to an intradermal solid tumor 
model in which a single solid tumor forms rather than multiple pulmonary nodules, allowing us 
to track tumor growth over time and easily isolate tumor infiltrating leukocytes (TIL).  To test 
the efficacy of vaccination in this model, female C57BL/6 mice were vaccinated with 105 PFU 
MCMVgp100KGP or mock vaccinated seven days prior to intradermal challenge with 105 
B16F10 melanoma cells.  As expected, vaccinated mice were protected from tumor challenge, 
showing significantly delayed tumor growth (Figure 4-1A).  In contrast, therapeutic vaccination 
three days following tumor challenge had minimal effect on tumor growth (Figure 4-1B).  This 
suggested that an established tumor microenvironment may severely limit the efficacy of 
vaccine-stimulated T cells.  There are several mechanisms that may explain this limitation, one 
of which is that vaccine-stimulated T cells fail to migrate into the tumor parenchyma.  To test 
this idea, mice were inoculated with B16F10 i.d. and vaccinated three days later.  Tumors were 
harvested and TIL isolated for flow cytometry.  Vaccinated mice had significantly more CD8+ 
TIL than unvaccinated mice, and CD8+ TIL expressed higher levels of the activation marker, 
CD11a in vaccinated mice vs. mock vaccinated (Figure 4-2A&B).  Though some of the CD8+ 
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TIL in vaccinated mice are likely MCMV-specific and not gp100-specific, this data nonetheless 
shows that MCMV-stimulated T cells can infiltrate a solid tumor, suggesting lack of T cell 
migration is unlikely to account for therapeutic inefficiency. 
PD-1 and CTLA-4 blockade do not improve antitumor response of therapeutic MCMV-
gp100KGP 
Immune checkpoint inhibitors against PD-1 and CTLA-4 have recently been approved for use in 
metastatic melanoma.58,66  PD-1 and CTLA-4 are inhibitory receptors expressed on the surface of 
activated T cells that limit T cell activation.  We asked whether TIL from MCMVgp100KGP 
vaccinated mice expressed these inhibitory receptors.  Around 50% of CD8+ TIL expressed PD-
1, regardless of whether mice received vaccination, while only 5% of CD8+ TIL expressed 
CTLA-4 (Figure 4-2C-F).  A previous study showed that PD-1 or CTLA-4 blockade could 
synergize with vaccination to B16 melanoma when given early in tumor progression.144  We 
therefore asked if checkpoint blockade could synergize with MCMVgp100KGP vaccination.  To 
this end, mice were inoculated with B16F10 i.d. and vaccinated with MCMVgp100KGP or mock 
vaccinated.  Mice either received anti-PD-1 on days 6, 9, and 12 (Figure 4-3B) or anti-CTLA-4 
on days 3, 6, and 9 (Figure 4-3C).  Neither therapy significantly delayed tumor growth compared 
to unvaccinated mice. 
Adoptive cell therapy targeting model neo-epitope enhances MCMVova vaccination 
Adoptive cell therapy is a form of immunotherapy that involves transferring high frequencies of 
ex vivo cultured tumor-reactive T cells into patients.  These tumor-reactive T cells are either 
isolated directly from tumor tissue and expanded in culture before transfer, or peripheral blood 
lymphocytes are genetically engineered to express a tumor-specific receptor.49  Importantly, 
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clinical response has been correlated with persistence of transferred cells in the patient, sparking 
a wave of interest in extending transferred cell survival.48  Several groups have tried to take 
advantage of the persistent nature of the T cell response to CMV to extend the survival of tumor-
reactive T cells.  Most of these efforts have focused on redirecting CMV-specific inflationary T 
cells to recognize tumor antigen.145-147  In a similar way, we hypothesized that CMV-based 
vaccines would promote persistence of adoptively transferred tumor-reactive T cells.  To test 
this, we first utilized a recombinant MCMV expressing the model antigen, ovalbumin 
(MCMVova).  MCMVova infection induces a robust inflationary T cell response that protects 
mice from challenge with B16 tumor cells expressing ova.129  We first asked if MCMVova could 
promote long-term persistence of adoptively transferred T cells.  C56BL/6 mice received 105 
OT-I T cells i.v., which express a transgenic T cell receptor recognizing SIINFEKL epitope 
within ovalbumin, followed by vaccination with 105 PFU WT MCMV or MCMVova.  As 
expected, OT-I cells expanded dramatically in response to MCMVova vaccination but were 
undetectable in mice vaccinated with WT MCMV (Figure 4-4A).  OT-I expansion peaked seven 
days after transfer and displayed a typical effector memory phenotype characterized as KLRG1+ 
CD127lo (Figure 4-4B). OT-I frequency progressively declined in 8/9 mice, while in one mouse, 
OT-I cells were maintained at high frequency over four months after transfer (Figure 4-4C).   
Our lab has previously shown that MCMVova delays tumor growth and improves survival in a 
metastatic model of melanoma.129  We hypothesized that adoptive cell therapy could synergize 
with MCMV-based vaccines to delay tumor growth.  Mice were inoculated with B16ova i.d. and 
eight days later received 105 OT-I cells i.v. followed by vaccination with WT MCMV or 
MCMVova.  Like in the metastatic model, MCMVova significantly delayed growth of an 
intradermal solid tumor, yet mice eventually succumbed to disease.  Adoptive cell transfer and 
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MCMVova vaccination significantly improved therapeutic efficacy and cured several mice 
(Figure 4-5).  This data shows that adoptive cell therapy can synergize with a persistent vaccine 
vector to cure mice, even if transferred cells do not persist long-term.  This may be a result of the 
dramatic expansion of OT-I cells early followed by the persistent endogenous OVA-specific 
response generated by MCMVova or the continued presence of endogenous OVA-specific T 
cells stimulated by MCMVova.   
MCMVgp100KGP is a more potent stimulatory of adoptively transferred gp100-specific T cells 
than VSVgp100KGP 
Given the dramatic results seen when combining adoptive cell therapy and MCMV vaccines 
targeting foreign antigens, we next asked whether this combination therapy would be as effective 
when targeting a shared tumor antigen.  For this, we utilized transgenic T cells (PMEL) 
expressing a T cell receptor recognizing the CD8+ T cell epitope gp10025-33.
148  We began by 
asking whether MCMVgp100KGP could stimulate adoptively transferred PMEL cells.  C57BL/6 
mice received 105 CD8+ PMEL cells i.v. followed by vaccination with PBS, WT MCMV, 
MCMV expressing native murine gp100 (MCMVgp100), or MCMVgp100KGP.  Five days later, 
only mice vaccinated with MCMVgp100KGP showed expansion of transferred PMELs (Figure 
4-6A).  Similar to the OT-I and MCMVova response, PMEL cells were not maintained long-term 
in the blood of mice vaccinated with MCMVgp100KGP (Figure 4-6B).  We next asked how 
MCMVgp100KGP stimulation compared to an acute viral vector, Vesicular Stomatitis Virus 
expressing gp100KGP (VSVgp100KGP).  Mice received 105 PMEL cells i.v. followed by 
vaccination with PBS, MCMVgp100KGP, or VSVgp100KGP.  Five days later, mice vaccinated 
with MCMVgp100KGP displayed a higher frequency of PMEL cells in blood compared to mice 
vaccinated with VSVgp100KGP.  This difference was also seen in peripheral blood and lungs 
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five (blood) and eight (lungs) months after vaccination (Figure 4-6C & Figure 4-7).  Thus, while 
MCMVgp100KGP did not sustain a very high frequency of PMEL cells after transfer, it 
generates more potent T cell responses compared to an acute viral vector. 
Adoptive cell therapy and MCMVgp100KGP vaccination significantly delays growth of 
established solid tumors 
As discussed above, prophylactic vaccination with MCMVgp100KGP significantly delays B16 
tumor growth, but therapeutic vaccination does not influence tumor growth.  In contrast, we 
found that vaccination with MCMVova potently delayed B16ova tumor growth.  This 
discrepancy may be partly attributed to the nature of the target antigen.  Because ova is a foreign 
antigen, high affinity T cells recognizing ova should not be hindered by central and peripheral 
tolerance mechanisms.  However, gp100 is a shared tumor antigen expressed in B16 melanoma 
as well as normal melanocytes.  Because of this, high affinity T cells recognizing gp10025-33 are 
deleted in the thymus during development.  Thus, any vaccine targeting gp100 is severely limited 
by a low precursor frequency.  We therefore hypothesized that increasing the precursor 
frequency of gp100-reactive T cells would enhance the effect of MCMVgp100KGP vaccination.  
As expected, combining MCMVgp100KGP vaccination with adoptive transfer of PMEL cells 
significantly delayed growth of established tumors, while either monotherapy had no effect on 
tumor growth (Figure 4-8).  Thus, like our results using MCMVova, adoptive cell therapy greatly 
enhances the efficacy of MCMV-based vaccines even though adoptively transferred cells do not 
persist at high frequency. 
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The tumor microenvironment induces the expression of several inhibitory receptors on the 
surface of MCMVgp100KGP-stimulated T cells 
Though tumor growth was delayed with adoptive cell therapy and vaccination, tumors continued 
to progress even with therapy.  We asked what factors may limit the efficacy of this therapy.  
The tumor microenvironment can greatly influence immune cell function.149,150  We first asked 
whether MCMVgp100KGP-stimulated T cells were influenced by the tumor microenvironment.  
To test this, tumor-bearing mice were treated with PMEL transfer and MCMVgp100KGP 
vaccination, and six days later, peripheral blood and tumor tissue were harvested for analysis by 
flow cytometry.  At this time point, PMEL cells made up 5-10% of CD8+ T cells from peripheral 
blood but constituted up to 50% of CD8+ T cells in tumor tissue, suggesting a preferential 
accumulation of these cells within the tumor tissue (data not shown).  PMEL cells isolated from 
tumor tissue expressed significantly more PD-1, LAG-3, 2B4, and NKG2A/C/E compared to 
PMEL cells isolated from peripheral blood (Figure 4-9).  PD-1, LAG3, and 2B4 are inhibitory 
receptors upregulated on exhausted T cells.  Expression of several of these receptors on T cells is 
associated with reduced effector function in exhausted T cells.151  Thus, our data suggests that 
the tumor microenvironment alters the functionality of PMEL cells and may limit the efficacy of 
out therapy. 
Inhibitory ligands are upregulated on tumor cells and tumor infiltrating leukocytes after 
vaccination with MCMVgp100KGP 
PD-1 binds its cognate ligand PD-L1 within the tumor microenvironment to limit T cell 
function.77  PD-L1 is upregulated in response to IFNγ, but it can also be constitutively expressed 
in some cancers.152  PD-L1 expression has also been postulated as a predictive marker for 
response to anti-PD-1 therapy.76,152  NKG2A is an inhibitory receptor expressed on the surface of 
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NK cells and CD8+ T cells.  NKG2A binding its cognate ligand, HLA-E in humans and Qa-1b in 
mice, limits CD8+ T cell function during infection and protects tumor cells from cytolysis.153,154  
Because PMEL cells within the tumor tissue expressed high levels of PD-1 and NKG2A, we next 
asked if PD-L1 and Qa-1b are also expressed in the tumor microenvironment.  To this end, mice 
were inoculated with B16F10 expressing red fluorescent protein (B16RFP) and left untreated, 
treated with PMEL transfer and WT MCMV vaccination, or treated with PMEL transfer and 
MCMVgp100KGP vaccination.  Six days later, tumor tissue was harvested for flow cytometry.  
Only 2% of B16RFP cells from culture expressed PD-L1 and less than 2% expressed Qa-1b 
(Figure 4-10A-C).  20-50% of RFP+ cells from untreated tumors and control treated tumors were 
PD-L1+ and about 5-20% were PD-L1+ and Qa-1b+.  In contrast, PMEL transfer and 
MCMVgp100KGP induced significant upregulation of PD-L1 and Qa-1b on RFP+ tumor cells 
(Figure 4-10A-C).  Essentially all tumor cells expressed PD-L1 and 50-60% of tumor cells 
expressed both PD-L1 and Qa-1b.  Similarly, both inhibitory ligands were also upregulated on 
CD45+CD8- tumor infiltrating leukocytes following MCMVgp100KGP vaccination (Figure 4-
10D-F).  This data highlights the highly dynamic nature of inhibitory ligand expression within 
the tumor microenvironment and shows that infiltration by tumor non-specific T cells (i.e. virus 
specific T cells following WT MCMV) does not induce a counter-regulatory response. 
Combination checkpoint blockade does not extend survival following MCMVgp100KGP 
vaccination 
Antibodies targeting PD-1 and PD-L1 are now approved therapies for metastatic melanoma.66  
Blocking antibodies against NKG2A are also in development for the treatment of cancer.155  
Given the high expression of these inhibitory pathways following MCMVgp100KGP 
vaccination, we hypothesized that these counter-regulatory pathways limit T cell function within 
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the tumor microenvironment.  We therefore asked if blockade of PD-1 and Qa-1b could 
synergize with MCMVgp100KGP vaccination to delay tumor growth.  Mice were inoculated 
with B16F10 and five days later were left untreated or received PMEL transfer and 
MCMVgp100KGP vaccination.  On days 10, 12, and 14, mice were treated with anti-PD-1 
and/or anti-Qa-1b and tumor growth measured every two to three days.  Anti-PD-1 therapy had a 
minor effect on survival, but neither anti-PD1, anti-Qa-1b, nor combination blockade 
significantly prolonged survival of vaccinated mice (Figure 4-11).   
MCMVgp100KGP vaccination induces accumulation of monocytic MDSCs and upregulation of 
IDO1 
Several studies have reported the induction of other immunosuppressive mechanisms in response 
to antitumor T cell activity.72,156  We therefore asked if MCMVgp100KGP vaccination increased 
the recruitment of other immunosuppressive cells to the tumor microenvironment.  To this end, 
mice were inoculated with B16F10 i.d. and left untreated, treated with PMEL transfer and WT 
MCMV vaccination, or treated with PMEL transfer and MCMVgp100KGP vaccination.  As 
expected, Thy1.1+ PMEL cells accumulated in tumor tissue in mice vaccinated with 
MCMVgp100KGP but not WT MCMV (Figure 4-12A).  In response to MCMVgp100KGP 
vaccination, we noted an impressive accumulation of Gr-1+CD11b+ myeloid cells which was not 
noted by PMEL transfer and vaccination with control viruses WT MCMV or MCMVgp100 
(Figure 4-12B).  Gr-1+ cells within the tumor microenvironment are generally characterized as 
Myeloid Derived Suppressor Cells (MDSCs).  The Gr-1 antibody recognizes both Ly6G and 
Ly6C on MDSCs, and therefore, labels two populations of MDSCs: monocytic-MDSCs 
characterized by Ly6C expression and granulocytic-MDSCs characterized by Ly6G 
expression.157  B16F10 tumors contained few Ly6G+ cells regardless of vaccination status 
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(Figure 4-12D).  In contrast, Ly6C+ myeloid cells greatly outnumbered Ly6G+ cells in all tumors 
and significantly increased in number following MCMVgp100KGP vaccination (Figure 4-12C).  
A previous study showed that adoptive transfer of in vitro activated PMEL cells induced a 
counter-regulatory recruitment of Ly6C+ MDSCs that potently inhibited T cell responses.156  We 
hypothesize that our results show an accumulation of these same previously described MDSCs. 
Indoleamine 2,3-dioxygenase 1 (IDO) is a cytosolic enzyme responsible for the degradation of 
tryptophan, and its expression is regulated by IFNγ.72,158  IDO is expressed in myeloid cells as 
well as tumor cells and has been shown to limit the response to checkpoint blockade.159-161  A 
recent study also showed that IDO expression by B16 melanoma resulted in the recruitment of 
monocytic-MDSCs within the tumor microenvironment.162  Given the significant accumulation 
of Ly6C+ myeloid cells in response to MCMVgp100KGP and the responsiveness of IDO to 
IFNγ, we hypothesized that MCMVgp100KGP would also upregulate IDO expression within the 
tumor and this upregulation may be partly responsible for the accumulation of Ly6C+ cells 
following MCMVgp100KGP vaccination.  As before, mice were inoculated with B16RFP i.d. 
and left untreated, treated with PMEL transfer and WT MCMV vaccination, or treated with 
PMEL transfer and MCMVgp100KGP vaccination.  Six days after treatment, IDO expression 
was trending upwards in RFP+ tumor cells from mice treated with MCMVgp100KGP 
vaccination but failed to reach statistical significance (Figure 4-13).  Thus, in addition to PD-L1, 
tumor cells also appeared to upregulate IDO (albeit at low levels) in response to antitumor T cell 
attack following MCMVgp100KGP vaccination. 
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Combination IDO inhibition and checkpoint blockade does not improve response to 
MCMVgp100KGP vaccination 
As stated above, IDO has been shown to inhibit antitumor T cell responses and diminish 
therapeutic responses to checkpoint blockade.161,163  Several inhibitors of IDO1 are entering 
clinical trials, including 1-methyl-tryptophan (1-MT).164  Given the enhanced expression of both 
PD-L1 and IDO in response to MCMVgp100KGP vaccination, we hypothesized that inhibition 
of these pathways would improve therapeutic responses to MCMVgp100KGP.  To test this, mice 
were inoculated with B16F10 i.d. and treated with PMEL transfer and MCMVgp100KGP 
vaccination five days later.  Starting on day 7, mice received 1-MT in their drinking water or 
control water.  Mice were also treated with anti-PD-1 blocking antibody; however, combination 
therapy did not influence tumor growth and did not extend survival of mice following 
vaccination (Figure 4-14).   
Combination chemo-immunotherapy delays tumor growth and prolongs survival of mice bearing 
established tumors 
Studies have shown that host preconditioning with chemotherapy or radiation can significantly 
enhance the effects of immunotherapy.165  Cyclophosphamide (CTX) is a commonly used 
alkylating agent that can synergize with immunotherapy.  At low doses, CTX can reduce 
numbers of immunosuppressive Tregs, and at high doses, it can modulate type I IFN signaling to 
enhance vaccination.166-168  We therefore asked if MCMVgp100KGP vaccination in combination 
with cyclophosphamide preconditioning could treat established tumors.  To test this, mice were 
challenged with B16F10 and six days later received a single 4mg dose of CTX.  The following 
day mice were treated with 105 in vitro activated PMEL cells, vaccination with 
MCMVgp100KGP, or both (Figure 4-15A).  CTX alone significantly delayed tumor growth 
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compared to untreated mice (Figure 4-15B).  MCMVgp100KGP vaccination alone, PMEL 
transfer alone, or PMEL transfer and WT MCMV vaccination did not delay tumor growth 
compared to CTX alone.  However, PMEL transfer and MCMVgp100KGP vaccination 
significantly delayed tumor growth compared to all other treatment groups.  Combination 
therapy also significantly prolonged survival, suggesting that combination therapy combining 
several therapeutic modalities may be most beneficial in delaying tumor growth (Figure 4-15C).   
Discussion:  
With the FDA approval of ipilimumab and nivolumab, cancer immunotherapy has finally 
become a standard treatment modality for some cancers.  Unfortunately, not all patients respond 
to these therapies.  Increasing evidence suggests that response is often seen in patients with 
tumors containing a high frequency of nonsynonymous mutations and high levels of T cell 
infiltration.41,42,73,77,134  These observations have led scientists and clinicians to distinguish 
tumors as “inflamed” i.e. containing many T cells or “non-inflamed” in which tumors-specific T 
cells are lacking.134,143  “Inflamed” tumors contain spontaneous T cell responses recognizing 
tumor antigen, yet these T cells are prevented from destroying malignant cells.  Patients with 
these kinds of tumors are more likely to benefit from checkpoint blockade than patients with 
“non-inflamed” tumors.  Therefore, novel methods for converting “non-inflamed” tumors into 
“inflamed” tumors are highly sought.  A potential method to do this is through vaccination 
against tumor antigen. 
Cytomegalovirus is a β-herpes virus that infects most individuals over the age of 40.80  This 
persistent infection induces a substantial expansion of CD8+ T cells recognizing viral antigens, 
and these T cells are maintained at high frequency over the lifetime of the host.95  Our lab has 
previously shown that a persistent vaccine vector based on murine Cytomegalovirus generates 
 53 
 
prolonged T cell responses against the melanoma antigen, gp100 and protects mice from a model 
of metastatic melanoma.129  However, mice eventually succumb to disease.   
In this study, we sought to determine if our vaccine MCMVgp100KGP would be effective 
against a solid intradermal tumor.  As hypothesized, prophylactic MCMVgp100KGP vaccination 
protected mice from an intradermal challenge of B16F10 melanoma.  However, therapeutic 
vaccination had no effect on tumor growth.  This inefficiency was not due to T cell exclusion 
from the tumor microenvironment as MCMVgp100KGP vaccination significantly increased the 
number of CD8+ T cells within the tumor.   
Adoptive cell therapy is an effective form of immunotherapy involving the transfer of large 
numbers of ex vivo cultured tumor-reactive T cells into patients.  One version of this therapy 
involves genetically engineering T cells to express tumor-specific receptors.26  Because most 
self-reactive T cells are deleted in the thymus during development, this form of therapy avoids 
the problem of vaccinating against self-antigens.  In this study, we asked whether 
MCMVgp100KGP was limited by the low precursor frequency of gp100-specific T cells.  Our 
previous results showed that about 2% of CD8+ T cells recognized gp100 following 
MCMVgp100KGP vaccination.129  Here, we show that following MCMVgp100KGP 
vaccination, PMEL cells made up 10-20% of circulating CD8+ T cells.  This increase in 
magnitude significantly delayed tumor growth, confirming our hypothesis that 
MCMVgp100KGP vaccination is limited by precursor frequency. 
Work within the field of adoptive cell therapy has shown that persistence of transferred cells 
correlates with clinical efficacy.48  Therefore, significant research is focused on identifying 
methods to improve the persistence of adoptively transferred cells.  Several groups have tried to 
utilize the persistent and ubiquitous nature of Cytomegalovirus to maintain adoptively 
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transferred cells.146,147  These studies have genetically engineered CMV-specific T cells to 
express a tumor-specific receptor with the thought that continuous stimulation through the 
endogenous CMV-specific TCR would maintain transferred cells long-term.  In this same line of 
thought, we hypothesized that a CMV-based vaccine could maintain adoptively transferred T 
cells long-term by continuously stimulating the expansion of these cells.  We tested this in two 
models.  MCMVova vaccination induced a massive expansion of adoptively transferred OT-I 
cells, but these cells were not maintained long-term.  Only one of nine mice showed a substantial 
maintenance of OT-I’s in peripheral blood several months after vaccination.  This is in contrast 
to a previous study by Turula et al. showing that infection with MCMVova maintained 
transferred OT-I’s at high frequency over time.169  This report also noted immune rejection of 
transferred OT-I’s in some mice due to minor allelic changes between mouse strains.  Though 
unlikely, this same rejection may account for the reduced persistence of OT-I’s in our study as 
well.  Another possible reason for this discrepancy is the number of transferred cells.  In the 
study by Turula et al., mice received 600 OT-I cells prior to infection, whereas our study 
involved the transfer of 105 OT-I cells.169  This difference in starting cell number may influence 
persistence of cells through clonal competition or reduction in viral load, which is known to 
influence MCMV T cell inflation.170  In a second model, we show that MCMVgp100KGP 
maintains transferred PMEL cells at higher frequencies than VSVgp100KGP, albeit still only at 
1% of total CD8+ T cells in peripheral blood.  PMEL cells were found at slightly higher 
frequencies in lungs of mice vaccinated with MCMVgp100KGP 263 days prior.  Thus, similar to 
MCMVova, MCMVgp100KGP maintains transferred antitumor T cells but at low frequency.  
Impressively, despite the decline in frequency of transferred cells over time, OT-I transfer and 
MCMVova vaccination cured several mice of B16ova, and PMEL transfer and 
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MCMVgp100KGP vaccination significantly delayed growth of B16F10 tumors.  These results 
highlight the potential of MCMV-based vaccines in combination with adoptive cell transfer and 
emphasize the difficulty in targeting a non-mutated shared tumor antigen.   
While adoptive transfer and MCMVgp100KGP vaccination delayed B16 tumor growth, mice 
eventually succumb to disease.  Many mechanisms exist that allow malignant cells to evade host 
immunity, and several of these pathways are highly upregulated in response to T cell attack, a 
process termed adaptive resistance.171  In response to T cell attack, “inflamed” tumors will 
upregulate counter-regulatory mechanisms like PD-L1 expression, IDO1 expression, and 
recruitment of regulatory immune cells.72  As stated above, patients who respond to current 
immunotherapies tend to show increased T cell infiltration within the tumor tissue and 
expression of these counter-regulatory pathways, suggesting an active immune response.   
B16F10 is notoriously difficult to treat with single agent immunotherapy and is characterized by 
low levels of immune cell infiltration relative to other murine tumors.163,172,173  We would 
therefore classify B16F10 as a “non-inflamed” tumor.  As discussed above, “non-inflamed” 
tumors are thought to be unresponsive to single agent immunotherapy due to lack of T cell 
infiltration within the tumor tissue.  In this study, we show that following PMEL transfer and 
vaccination with MCMVgp100KGP PMEL cells accumulate within the tumor tissue at high 
frequency, suggestive of an “inflamed” tumor microenvironment.  We also show upregulation of 
several inhibitory pathways (PD-L1, Qa-1b, IDO1, and mo-MDSCs recruitment) following T cell 
infiltration.  Thus, at least by these parameters, our data suggests that vaccination against a 
shared tumor antigen can produce an “inflamed” tumor phenotype.   
Surprisingly, we were unable to enhance the efficacy of vaccination by checkpoint blockade or 
inhibition of IDO.  Expression of PD-L1 has been investigated as a predictive biomarker for 
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response to antibodies blocking PD-1 or PD-L1.152  A previous study in murine pancreatic cancer 
showed that vaccination induced expression of PD-L1 and synergized with PD-1 blockade; 
however, this same study showed that tumors were also responsive to PD-1 blockade without 
vaccination.174  Our results suggest that even in the presence of high levels of PD-L1, established 
B16F10 tumors are still resistant to PD-1 blockade.  Previous studies have shown that PD-1/PD-
L1 blockade can synergize with anti-CTLA-4 and IDO inhibitors.161,163  However, these studies 
began combination therapy early after tumor challenge or in tumors expressing a foreign model 
antigen.  Our studies with B16ova show that presence of a foreign antigen can greatly impact the 
efficacy of immunotherapy, but the relevance of these models to human disease is unclear.  In 
our studies, we show that the parental B16F10 model is much more resistant to immunotherapy.  
To better model clinical disease, we also initiated therapy after tumors were visible and the 
tumor microenvironment was established.  These differences in experimental design may explain 
the discrepancy in response to anti-PD-1 therapy in this tumor. 
NKG2A is an inhibitory receptor expressed on the surface of NK cells and activated T 
cells.153,155  The expression of its ligand, HLA-E, in human tumor cells prevents T cell-mediated 
cytotoxicity through NKG2A engagement.154  Like MHC Class I molecules and PD-L1, HLA-E 
and its murine homolog, Qa-1b, are upregulated in response to IFNγ.175,176  Our results show that 
Qa-1b is highly upregulated in response to vaccination with MCMVgp100KGP.  We also noted a 
high percentage of PMEL cells expressing NKG2A within the tumor microenvironment, 
suggesting a potential mechanism for immunoevasion.  However, blockade of Qa-1b had no 
effect on tumor growth following vaccination.  A potential reason for this may be redundant 
inhibitory checkpoint signaling through other receptors.  In our studies, PMEL cells also express 
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high levels of LAG3 and 2B4 within the tumor microenvironment.  These pathways may also 
restrict the efficacy of vaccine-stimulated T cells. 
Several other counter-regulatory mechanisms may account for the resistance of B16F10 tumors 
to vaccination.  As we have shown, MCMVgp100KGP vaccination results in the recruitment of 
Ly6C+ MDSCs to the tumor microenvironment.  A previous study by Hosoi et al. showed that 
adoptive transfer of tumor-specific T cells results in the recruitment of Ly6C+ MDSCs that limit 
T cell function.156  We also noted a slight, but insignificant upregulation of IDO1 in tumor cells 
following vaccination.  IDO1 expression in tumor cells is known to induce the recruitment of 
MDSCs in B16 tumors and increase resistance to immunotherapy.162  IDO inhibitors have been 
evaluated in several preclinical tumor models and are currently being tested in combination with 
checkpoint inhibitors in patients with metastatic melanoma (NCT02073123; 
NCT02752074).161,163  Unfortunately, our initial experiments suggest that an IDO inhibitor with 
or without anti-PD1 therapy does not prolong of mice vaccinated with MCMVgp100KGP.   
In summary, this study shows that MCMV-based vaccines can significantly impact tumor growth 
particularly when combined with adoptive cell transfer.  Vaccines targeting foreign antigens 
were more effective in tumor rejection, suggesting that MCMV-based vaccines targeting neo-
epitopes may be a more effective strategy to eliminate immunotherapy resistant tumors.  Here, 
we also show that several immunosuppressive pathways are upregulated in response to 
MCMVgp100KGP vaccination, including PD-L1, Qa-1b, IDO1, and expansion of regulatory 
immune cells.  These pathways highlight an ongoing immune response within the tumor 
environment and also suggested potential points of intervention for combination immunotherapy.  
Unfortunately, we were unable to improve antitumor activity of MCMVgp100KGP vaccination 
by inhibiting several of these pathways, suggesting that other pathways may be responsible for 
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tumor relapse.  We have not yet tested the effects of targeting MDSCs with MCMVgp100KGP 
vaccination, but several studies have shown that targeting these cells can improve responses to 
combination therapy.177,178  Tumor necrosis and hypoxia have also been shown to limit the 
activity of antitumor T cells.179,180  In summary, this study shows that a persistent vaccine vector 
can dramatically transform the phenotype of a “non-inflamed” tumor; however, expression of 
several clinically-relevant immunosuppressive pathways following vaccination does not correlate 
with increased sensitivity to inhibitors of these pathways.  Future work looking at the role of 
recruited MDSCs will investigate another potential role of resistance.  Our data also suggests that 
CMV-based vaccines targeting neo-epitopes may be a highly effective method for fighting 
melanoma. 
Figures: 
 
Figure 4-1: Prophylactic but not therapeutic MCMVgp100KGP delays intradermal solid 
tumor growth. A) Prophylactic vaccination with MCMVgp100KGP 7 days prior to challenge 
with B16F10 cells significantly delays tumor growth.  B) Therapeutic vaccination with 
MCMVgp100KGP 3 days after tumor challenge does not significantly delay tumor growth.    
n=5 mice/group for A) and 6-7 mice/group for B); n.s. Not significant; p>0.05; *p<0.05. 
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Figure 4-2: Vaccination increases number and activation status of CD8+ TIL but does not 
influence inhibitory receptor expression.  Mice were treated with MCMVgp100KGP 3 days 
after tumor challenge and TIL were harvested 15 days later for flow cytometry.  Vaccination 
increases A) total number of CD8+ TIL and B) expression of CD11a on CD8+ TIL.  Vaccination 
does not change C) percentage of CTLA-4+CD8+ TIL, D) CTLA-4 MFI on CD8+ TIL, E) 
percentage of PD-1+ CD8+ TIL, and E) PD-1 MFI on CD8+ TIL. n=5-6/group; **p<0.01. 
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Figure 4-3: Checkpoint blockade does not synergize with therapeutic MCMVgp100KGP 
vaccination.  A) Experimental schema for B) and C).  Three days after tumor challenge, mice 
were vaccinated with MCMVgp100KGP or mock vaccinated and treated with B) anti-PD-1 on 
days 6, 9, and 12 or C) anti-CTLA-4 on days 3, 6, and 9.  Control mice received isotype control 
antibodies.   
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Figure 4-4: MCMVova stimulates adoptively transferred OT-I cells but does not maintain 
them long-term.  C57BL/6 mice received 105 CD45.1+ OT-I CD8+ T cells i.v. followed by 
vaccination with 105 PFU WT MCMV or MCMVova i.p.  A) Seven days after transfer, OT-I 
cells are found at high frequency in peripheral blood of mice vaccinated with MCMVova but not 
WT MCMV.  B) OT-I cells display an effector memory phenotype (KLRG1+CD127lo) seven 
days after transfer.  C) Frequency of OT-I cells in peripheral blood of MCMVova vaccinated 
mice from two separate experiments.  One of nine mice showed a high frequency of OT-I cells 
four months after vaccination.  Results are representative of two independent experiments. 
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Figure 4-5: Adoptive cell therapy and MCMVova cure mice with established B16ova 
tumors.  Mice bearing B16ova tumors were treated with 105 naïve OT-I cells, vaccination with 
MCMVova, OT-I transfer and WT MCMV vaccination, or OT-I transfer and MCMVova 
vaccination.  A) Tumor growth curves of individual mice in each treatment group.  B) Survival 
curves of treated mice.  Results are representative of 3 independent experiments with 5 
mice/group. ***p<0.001 
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Figure 4-6: MCMVgp100KGP stimulates adoptively transferred PMEL cells.  A) C57BL/6 
mice received 105 CD8+ Thy1.1+ PMEL cells followed by vaccination with PBS, WT MCMV, 
MCMVgp100, or MCMVgp100KGP.  Frequency of Thy1.1+ cells in peripheral blood five days 
after vaccination.  B) Frequency of Thy1.1+ cells in peripheral blood of mice vaccinated with 
MCMVgp100KGP.  C) Frequency of Thy1.1+ cells in peripheral blood of mice vaccinated with 
MCMVgp100KGP or VSVgp100KGP 5 or 160 days after vaccination.  n=3 mice/group; 
**p<0.01 
 64 
 
 
Figure 4-7: MCMVgp100KGP maintains PMEL cells in lungs long-term. Transferred PMEL 
cells are detected in lungs of mice vaccinated with MCMVgp100KGP but not VSVgp100KGP 
263 days following transfer.  A) Flow cytometry plots from individual mice.  B) Representative 
plot showing effector memory phenotype of PMEL cells in lungs of mice vaccinated with 
MCMVgp100KGP 263 days prior. n=3 mice/group. 
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Figure 4-8: Adoptive cell therapy and MCMVgp100KGP vaccination delays growth of 
established B16 tumors.  Mice were challenged with B16F10 5 days prior to transfer of 105 
CD8+ PMEL cells and vaccination with WT MCMV or MCMVgp100KGP.  A) Individual tumor 
growth curves.  B) Combined tumor growth curves.  Statistical differences are noted as: 
PMEL+MCMVgp100KGP vs. Mock Treated *; PMEL+MCMVgp100KGP vs. PMEL *; 
PMEL+MCMVgp100KGP vs. PMEL+WT MCMV*; PMEL+MCMVgp100KGP vs. 
MCMVgp100KGP*.  C) Survival curves.  Data was combined from two independent 
experiments with 5 mice/group.  One mouse from PMEL+MCMVgp100KGP group did not 
grow a tumor over the course of the experiment and was excluded from the analysis.  *p<0.05; 
**p<0.01   
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Figure 4-9: MCMVgp100KGP stimulated T cells upregulate inhibitory receptors in tumor 
microenvironment. Tumor bearing mice were treated with PMEL transfer and 
MCMVgp100KGP vaccination.  Six days later, blood and tumor tissue were harvested for flow 
cytometry.  A). Representative plots showing expression of inhibitory receptors on PMEL cells 
from blood or tumor in the same mouse.  B) MFI of inhibitory receptors on PMEL cells from 
blood compared to MFI on PMEL cells isolated from tumors in the same mouse.  n=4 mice.  
Data representative of at least 2 independent experiments.  *p<0.05; ***p<0.001 
 67 
 
 
 
 68 
 
Figure 4-10: Combination immunotherapy induces expression of inhibitory ligands in vivo.  
Five days after challenge with B16RFP, mice were left untreated, treated with PMEL transfer 
and WT MCMV vaccination, or treated with PMEL transfer and MCMVgp100KGP vaccination.  
Six days later, tumor cells were harvested for flow cytometry.  A) Representative flow plots of 
RFP+ cells.  B) Percentage of RFP+ cells expressing C) PD-L1 and D) both PD-L1 and Qa-1b.  D) 
Representative plots of CD45+CD8-RFP- cells.  Percentage of CD45+CD8-RFP- cells 
expressing A) PD-L1 and B) both PD-L1 and Qa-1b.  Representative of two independent 
experiments with n=4-5 mice/group.  *p<0.05; ***p<0.001 
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Figure 4-11: PD-1 and Qa-1b blockade do not enhance antitumor effects of 
MCMVgp100KGP immunotherapy.  Mice were challenged with B16F10 and five days later 
treated with PMEL transfer and MCMVgp100KGP vaccination.  Mice received anti-PD-1, anti-
Qa-1b, or both on day 10, 12, and 14.  Untreated mice or mice receiving monotherapy also 
received isotype control antibodies.  A) Individual tumor growth curves and B) survival curves 
of mice receiving combination immunotherapies.  Data combined from two independent 
experiments. n=10 mice/group. 
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Figure 4-12: MCMVgp100KGP vaccination induces accumulation of monocytic MDSCs.  
Mice bearing B16F10 tumors were left untreated, treated with PMEL transfer and WT MCMV 
vaccination, or treated with PMEL transfer and MCMVgp100KGP vaccination.  Six days after 
treatment, tumors were processed for flow cytometry.  Numbers of A) Thy1.1+ PMEL cells, B) 
Gr-1+CD11b+ cells, C) Ly6C+CD11b+ cells, and D) Ly6G+CD11b+ cells were normalized to 
initial tumor weight.  A, C, and D are representative of three independent experiments with n=4-
5 mice/group.  B is representative of one experiment.  *p<0.05; **p<0.01; ***p<0.001 
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Figure 4-13: MCMVgp100KGP vaccination slightly upregulates expression of IDO in 
tumor cells.  Mice were inoculated with B16RFP tumors via intradermal injection and 5 days 
later left untreated, treated with PMEL transfer and WT MCMV vaccination, or treated with 
PMEL transfer and MCMVgp100KGP vaccination.  Six days later tumors were processed for 
flow cytometry.  A) Percentage of RFP+ tumor cells expressing IDO.  B) MFI of IDO in RFP+ 
tumor cells relative to isotype control.  C) Representative figure of IDO expression in RFP+ 
tumor cells.  Data for A) and B) were compiled from two independent experiments with 9-10 
mice/group. 
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Figure 4-14: IDO inhibitor does not enhance response to combination immunotherapy.  
Mice were challenged with B16F10 tumors and were treated with PMEL transfer and 
MCMVgp100KGP vaccination five days later.  On day 10, mice were started on 2mg/mL 1-
methyltryptophan (1-MT) in the drinking water or control water.  Mice were also treated with 
anti-PD1 or isotype control on days 10, 13, and 18.  n=5 mice/group. 
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Figure 4-13: Combination chemo-immunotherapy significantly delays tumor growth.  A) 
Schematic of experimental design.  Mice were challenged with B16F10 six days prior to 
receiving one dose of cyclophosphamide.  On day 7, mice received 105 in vitro activated PMEL 
cells and vaccination with WT MCMV or MCMVgp100KGP.  B) Tumor growth curves and C) 
survival curves show combination chemo-immunotherapy significantly delays growth of 
established tumors.  Data is representative of 3 independent experiments with n=5 mice/group.  
***p<0.001 
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Chapter 5: Identification of Novel CD169+ Macrophage Population 
within Melanoma Tumors 
 
Abstract: 
Malignant tissue is often inundated with myeloid cells of diverse phenotype.  Tumor associated 
macrophages make up a large proportion of tumor myeloid cells and generally are thought to 
promote tumor progression.  Macrophages expressing the marker CD169 have critical roles in 
filtering lymph in lymph nodes and blood in the spleen and are thought to be critical to initiating 
the adaptive immune response.  Here we show that CD169+ macrophages are present in high 
frequency in murine melanoma and these macrophages are phenotypically distinct from skin 
resident macrophages, and preferentially ingest tumor particles.  Future work will determine the 
effect of CD169+ macrophages in tumor growth. 
Introduction: 
Cancerous tissue is often infiltrated by high frequencies of myeloid cells.  Tumor associated 
macrophages (TAMs) are a diverse group of cells making up a large percentage of tumor 
infiltrating leukocytes.181,182  In many cancers, increasing frequencies of TAMs are associated 
with reduced overall survival.183  This association has also been confirmed in patients with 
melanoma, leading to the predominate hypothesis that TAMs are generally protumorigenic.184  
The plasticity of macrophages under diverse environmental conditions often makes the study of 
their functions difficult, particularly in vivo.185  However, studies have shown that TAMs can 
influence tumor growth through a variety of mechanisms, including increased tumor 
angiogenesis, promotion of metastasis and invasive characteristics of tumor cells, and 
suppression of antitumor T cell responses.186   
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CD169+ macrophages represent a subset of myeloid cells largely studied within lymphoid 
tissues.  Within the spleen and lymph nodes, CD169+ macrophages act as filters to capture 
microbes and exposed antigens in blood or lymph, initiating the activation of lymphocytes within 
these tissues.187  A handful of studies have begun to investigate the role of these cells in tumor 
immunity.  A study by Asano et al. showed that CD169+ macrophages in the draining lymph 
nodes of mice phagocytose dead tumor cells following subcutaneous vaccination, and these cells 
are required for vaccine efficacy by cross-presenting tumor antigen and priming antitumor T 
cells.188  Similarly, a study by Pucci et al. showed that CD169+ macrophages within lymph nodes 
captured extracellular vesicles produced by tumor cells, and this capture prevented activation of 
tumor-promoting B lymphocytes.189   
Several clinical studies have also illustrated the significance of CD169+ lymph node 
macrophages as predictive biomarkers for cancer progression.190,191  In melanoma patients, 
specifically, higher densities of these macrophages in regional lymph nodes correlated with 
prolonged survival and greater infiltration of tumor tissue by CD8+ T cells.192  Like the mouse 
models, these studies suggest that CD169+ macrophages in lymphoid tissue are involved in 
priming antitumor T cells.  In the current study, we show for the first time that CD169+ 
macrophages are not only localized to draining lymph nodes but are also found directly within a 
solid melanoma tumor.  These cells appear in high frequency in the tumor tissue, are 
phenotypically distinct from skin-resident macrophages, and may phagocytose tumor cell 
particles more efficiently than CD169- TAMs.   
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Results: 
Intradermal B16 tumors contain a novel CD169+ macrophage subset that are distinct from skin 
resident macrophages 
Given the diversity of myeloid cells seen in different tumors and the potential of CD169+ 
macrophages to elicit antitumor immunity in lymph nodes, we asked whether B16F10 melanoma 
tissue contained CD169+ TAMs.  Surprisingly, B16F10 tumors were inundated with CD169+ 
cells (Figure 5-1).  These cells were F4/80+ by immunofluorescence imaging and flow 
cytometry, confirming their identity as TAMs (Figures 5-1 and 5-2A).  CD169+ TAMs expressed 
high levels of Fc gamma receptor 1 (CD64) and CSF1R (CD115), further confirming their 
myeloid identity (Figure 5-2B).  Interestingly, CD169+ TAMs expressed only low levels of 
CCR2 which is a key chemokine receptor for monocyte recruitment (Figure 5-2B).  
Impressively, CD169+ TAMs uniformly expressed high levels of MHCII, while CD169-F4/80+ 
TAMs contained a significant MHCIIlo population (Figure 5-2C).   
Intradermal CD169+ macrophages are phenotypically distinct from skin resident macrophages 
Previous studies have shown that tumor tissue contains both tissue-resident macrophages and 
monocyte-derived macrophages.181  CD169+ macrophages have been described in healthy skin, 
predominately within the dermal layer.193,194  We therefore asked if CD169+ TAMs were 
phenotypically distinct from skin resident macrophages.  Like previous studies, we detected a 
subpopulation of macrophages in skin from naïve mice expressing CD169 (Figure 5-3A).  Skin 
resident CD169+ macrophages contained a distinct CD11c+MHCII+CCR2+ subpopulation (Figure 
5-3B).  In contrast, CD169+ TAMs uniformly expressed MHCII and low levels of CCR2 (Figure 
5-3C), showing that CD169+ TAMs are phenotypically distinct from skin resident macrophages.  
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As previously stated, the majority of TAMs in other tumor models are derived from recruited 
circulating monocytes.181  We hypothesize that CD169+ TAMs are also derived from circulating 
monocytes rather than skin resident macrophages.  Future studies will examine this more closely. 
CD169+ TAMs ingest tumor particles within the tumor microenvironment 
As already stated, CD169+ macrophages in lymphoid tissues are thought to efficiently 
phagocytose tumor derived particles by filtering draining lymph.188,189  We therefore 
hypothesized that CD169+ TAMs might also efficiently internalize tumor fragments.  To test 
this, mice were inoculated via intradermal injection with B16F10 expressing Red Fluorescent 
Protein (B16RFP).  Eleven days later, tumor tissue was harvested and processed for flow 
cytometry.  As hypothesized, some CD169+ macrophages also expressed low levels of RFP, 
suggesting internalization of tumor fragments (Figure 5-4A).  Impressively, of all F4/80+ cells 
co-expressing RFP, the majority were CD169+, signifying preferential phagocytosis by CD169+ 
TAMs (Figure 5-4B).  We also noted high expression of MHCII and the costimulatory ligand, 
CD80 on CD169+ macrophages, suggesting a preferential ability to prime T cells (Figure 5-4C).   
While this flow cytometry data suggests internalization of tumor fragments by CD169+ 
macrophages, it is possible that these macrophages take up tumor fragments during processing 
for flow cytometry.  We therefore stained fixed sections of B16RFP tumors for CD169.  Imaging 
revealed many CD169+ TAMs in close association with RFP+ tumor cells (Figure 5-5) and some 
contained punctate RFP+ signals, confirming internalization of tumor particles in vivo (Figure 5-
6).  Thus, CD169+ macrophages may be well-equipped to internalize and process tumor antigen 
not only at lymphoid tissues but also within the tumor microenvironment. 
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Discussion: 
Infiltration of tumor tissue by macrophages has been associated with poor prognosis for patients 
with several types of malignancy.183,184  The mechanisms behind this observation are probably 
diverse as TAMs can influence disease progression through several pathways including 
angiogenesis and immunosuppression.186  Tumor tissue can contain several subsets of 
macrophages with different phenotypic characteristics.  Some of these macrophages are derived 
from proliferating tissue-resident macrophages, but the majority of TAMs are thought to 
originate from blood-derived monocytes that differentiate within the tumor microenvironment.181   
Lymph node resident CD169+ macrophages have been implicated in the priming of antitumor 
immunity in preclinical models by capturing and cross-presenting tumor antigen to prime 
antitumor T cells.188  In patients, the density of these cells in regional lymph nodes correlates 
with increased T cell infiltration of tumor tissue and increased overall survival.190-192  Thus, 
CD169+ cells within the lymph node appear to be critical in regulating antitumor immunity. 
In this study, we discovered that a significant number of cells express CD169 within the tumor 
microenvironment.  These cells were confirmed to be TAMs by co-staining for the macrophage 
markers, CD64 and F4/80.  While our data shows that CD169+ TAMs are phenotypically distinct 
from skin resident macrophages, it is still unclear whether CD169+ TAMs arise from skin 
resident macrophages that respond to the growing tumor or whether they differentiate from 
circulating peripheral monocytes.  Future studies will dissect the origin of these cells.   
CD169+ TAMs uniformly expressed high levels of MHCII and CD80, suggesting a potential 
ability to activate antitumor T cells.  In contrast, CD169- TAMs contained populations of 
MHCIIlo and MHCIIhi cells and expressed lower levels of CD80.  Surprisingly, our preliminary 
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data also suggests an ability of CD169+ cells to ingest fragments of tumor cells.  With these 
properties, we hypothesize that CD169+ TAMs have the ability to stimulate rare antitumor T 
cells within the tumor microenvironment.  A previous study using clinical samples from patients 
with hepatocellular carcinoma has also described CD169+ TAMs which express high levels of 
HLA-DR and CD86.  This same study also showed that the density of CD169+ TAMs correlated 
with intratumoral CD8 T cell density and overall patient survival.195  Our future studies will test 
the ability of CD169+ TAMs to stimulate antitumor T cells and investigate the role of these cells 
in melanoma tumor progression.   
 
 
Figure 5-1: Intradermal B16F10 tumors contain a high density of CD169+ TAMs.  Mice 
were inoculated with B16F10 tumor cells via intradermal injection.  Established tumors were 
fixed in PLP buffer and cut into 20µm sections before staining antibodies against CD169 (red), 
F4/80 (dark blue), CD8 (light blue).  Scale bar=50µm. 
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Figure 5-2: Phenotypic characterization of CD169+ TAMs.  Intradermal B16F10 tumors were 
processed into single cell suspension and stained for flow cytometry.  A) CD169 staining of 
tumor infiltrating leukocytes, gated on live CD45+ cells.  B) CD169+ TAMs express CD115, 
CD64, and low levels of CCR2.  C) CD169+ TAMs express high levels of MHCII, while CD169- 
TAMs show diverse MHCII expression.  n=3 mice.  Representative of at least two independent 
experiments, except CD64 staining which is representative of one experiment. 
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Figure 5-3: Skin resident CD169+ macrophages are phenotypically distinct from TAMs.  A) 
CD169+ macrophages are found in skin from healthy mice.  B) CD169+ macrophages from 
healthy skin consist of two populations: MHCII+CCR2+CD11c+ and MHCII-CCR2-CD11c- 
populations.  C) CD169+ TAMs from B16F10 tumors are uniformly MHCII+ and express low 
levels of CCR2 and CD11c.  n=3 mice/group. 
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Figure 5-4: CD169+ TAMs engulf tumor particles in untreated solid tumors.  Mice were 
inoculated with B16RFP.  Tumors and spleen were harvested 11 days later for flow cytometry.  
A) CD169+ F4/80+ TAMs show increased fluorescence in the RFP channel compared to CD169-
F4/80+ TAMs from the same tumors.  B) The majority of RFP+ TAMs are CD169+.  RFP gating 
was based on staining in spleen which should not contain RFP+ cells.  C) CD80 expression on 
CD169+ TAMs and CD169- TAMs.  n=4 mice. 
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Figure 5-5: CD169+ TAMs interact with B16RFP tumor cells in close proximity.  Mice were 
inoculated with B16RFP tumors and 11 days later, tumors were PLP fixed, sectioned into 20µm 
sections, and stained for CD169.  Top row shows B16RFP tumors without CD169 staining.  
Bottom two rows show RFP (red) and CD169 (blue) in close proximity within the tumor.  
Arrows indicate CD169+ TAMs in close proximity to B16RFP tumor cells. n=2 mice; Scale 
bar=80µm.   
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Figure 5-6: CD169+ TAMs ingest RFP+ tumor particles within the tumor 
microenvironment.  Mice were inoculated with B16RFP tumor cells and 11 days later tumors 
were harvested and fixed by PLP fixation.  Tumors were cut into 20µm sections and stained for 
CD169.  Arrows indicate CD169+ TAMs (blue) with internalized RFP+ particles (red). n=2 mice; 
Scale bar=80µm.  
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Chapter 6: Summary and Future Directions 
Cytomegalovirus-based Tumor Vaccines 
Cytomegalovirus (CMV) is a ubiquitous herpes virus that generates a unique T cell response 
termed “memory inflation”.  This phenomenon is characterized by the maintenance of a high 
frequency of virus-specific T cells over the lifetime of the host.  In contrast to other chronic 
infections, CMV-specific T cells maintain effector function over time.95,105  Impressively, this 
unique T cell response is still observed after vaccination with a single-cycle virus, limiting the 
danger of viral reactivation.116  These properties make CMV an attractive platform for vaccines 
targeting infectious diseases and cancer.   
Our lab has previously generated a Murine Cytomegalovirus (MCMV) vaccine vector expressing 
an alter melanoma antigen (MCMVgp100KGP) that delays murine melanoma growth.129  In this 
study, we sought to generate a novel MCMV vaccine expressing both gp100KGP and a second 
altered melanoma antigen.  In the process, we show that a MCMV based vaccine expressing both 
gp100KGP and the native melanoma antigen, Trp2 is unable to delay tumor growth compared to 
MCMVgp100KGP, highlighting the difficulty of vaccinating against self-antigens.  We 
anticipated this result and therefore simultaneously constructed a MCMV vector expressing 
gp100KGP and an altered Trp2.  However, by altering Trp2 at one amino acid, we drastically 
reduced the expression of the full-length protein.  Not surprisingly, this vector also did not 
improve antitumor activity compared to MCMVgp100KGP.  While this study did not generate a 
more effective melanoma vaccine, it does highlight a potential pitfall in altering T cell epitopes 
within full-length proteins in an expression vector.  A previous study by Klyushnenkova et al. 
showed that a MCMV-based vaccine expressing a T cell epitope in prostate-specific antigen was 
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more effective than one expressing the full-length protein.126  Thus, future CMV-based vaccines 
may be more effective if designed to express shorter peptides corresponding to T cell epitopes 
rather than full-length proteins.  Another potential pitfall for CMV-based vaccines may be the 
incorporation of several epitopes within the same vaccine vector.  Research has shown that 
inserting a foreign antigen into a MCMV vector reduces the endogenous virus-specific 
inflationary T cell response.  However, when these epitopes are expressed in two different 
viruses, inflationary T cell responses were not restrained, suggesting that inflationary epitopes 
compete within infected cells for antigen presentation.196  Thus, targeting different tumor 
antigens using several CMV-based vectors may be more effective than multiple-epitope vectors.  
Future work will test several MCMV-based vaccines each expressing altered T cell epitopes 
within established melanoma antigens.  In addition, targeting novel epitopes created as a result of 
tumor mutation (termed neo-epitopes) may yield more dramatic results.  As methods for 
predicting immunogenic neo-epitopes improves, CMV-based vaccines may be an effective 
vaccine formulation to induce lifelong T cell responses specifically recognizing tumor antigen.   
Combining CMV-based Vaccines with Other Immunotherapies 
This study extends previous work by our lab investigating the impact of MCMV-based vaccines 
for the treatment of melanoma.  Herein, we show that MCMV expressing tumor antigens can 
delay tumor growth in an aggressive solid tumor model of B16 melanoma.  We also show that 
vaccine efficacy is limited by the precursor frequency of tumor-reactive T cells.  As 
hypothesized, combining MCMV vaccination with adoptive cell therapy significantly delays 
tumor growth compared to either therapy alone.   
In this study, we also show that combination adoptive cell transfer and MCMV vaccination 
significantly upregulates the expression of several immunosuppressive pathways directly within 
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the tumor microenvironment.  B16 melanoma is generally considered to be a non-immunogenic 
tumor model as checkpoint inhibitor monotherapy has little effect on established tumor 
growth.163,197  Clinical responses to immune checkpoint therapy has been associated with 
increased T cell infiltration, mutational load, and PD-L1 expression.39,41,76  This has led scientists 
to distinguish tumors as “inflamed” or “non-inflamed” based on the presence of T cell infiltrate 
and inhibitory pathway expression.143  Our data suggests that CMV-based vaccination can at 
least partly induce an “inflamed” phenotype in an aggressive tumor model.  However, in contrast 
to clinical studies suggesting that expression of inhibitory ligands in the tumor 
microenvironment, we did not discover enhanced responsiveness to PD-1, NKG2A, or IDO 
inhibition following vaccination, despite high expression of several of these pathways.  As 
previously discussed, several other pathways may be limiting vaccine efficacy, including 
expression of other inhibitory receptors like LAG-3 and 2B4 or recruitment of regulatory cells 
like MDSCs.  Molecules targeting these pathways may be useful in this tumor model.  For 
instance, CSF1R antagonists have been shown to limit the influence of MDSCs within the tumor 
microenvironment.178  More broadly, several studies have noted that tumor necrosis and tissue 
hypoxia can limit T cell activity within the tumor microenvironment, providing other potential 
mechanisms for immune resistance.179,180,198  Future studies will determine if inhibitors of these 
pathways may enhance antitumor activity of MCMV-based vaccines.   
The most promising results from our studies include the eradication of tumors in mice treated 
with adoptive cell therapy and MCMVova.  This data suggests that CMV-based vaccines 
targeting neo-epitopes may be highly effective immunotherapies, even in these highly aggressive 
tumors.  One study has already tested traditional peptide-based vaccines targeting neo-epitopes 
in B16 melanoma, showing a significant delay in tumor growth.35  These results may be even 
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more dramatic in the context of an inflationary T cell response against these epitopes.  Thus, 
future work will seek to generate several MCMV-based vaccines targeting tumor-specific 
antigens.   
Elucidating the Role of CD169+ Macrophages within the Tumor Microenvironment 
Tumor associated macrophages (TAMs) make up a large frequency of tumor infiltrating 
leukocytes and have generally been associated with poor prognosis in several cancers.183,184  In 
contrast, CD169+ macrophages within the regional lymph nodes seem to contribute to antitumor 
immunity, as higher densities of these macrophages correlate with CD8+ T cell infiltration of 
tumor tissue and overall survival in melanoma.192  In preclinical models, these cells are essential 
for capturing tumor antigen within the draining lymph node and activating CD8+ T cells while 
preventing activation of tumor-promoting B cells.188,189 
Here, we have shown that CD169+ macrophages are also found at relatively high frequency 
directly within B16 melanoma tumors.  Few studies have described this subpopulation of 
macrophages directly within the tumor microenvironment.  In one such study, CD169+ TAMs in 
hepatocellular carcinomas displayed high levels of MHCII and CD86, and CD169+ TAM density 
correlated with CD8+ T cell infiltration and overall patient survival, suggesting a critical role for 
these macrophages in antitumor immunity.195  In our own current study, we show that CD169+ 
TAMs from B16F10 tumors also express high levels of MHCII and the costimulatory molecule 
CD80.  Impressively, we also show preliminary evidence that CD169+ TAMs can engulf tumor 
particles directly within the tumor microenvironment.  All of these results lead us to hypothesize 
that CD169+ TAMs may represent a subpopulation of TAMs capable of capturing and presenting 
tumor antigen to T cells directly within the tumor microenvironment.  We have already begun 
trying to record CD169+ TAM capture of tumor particles using intravital two photon imaging and 
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CD169 reporter mice to further confirm this ability in these cells.  Future work will also test the 
ability of these cells to stimulate T cells.  By FACS sorting CD169+ and CD169- TAMs directly 
from B16 tumors, we will compare the ability of these two populations to stimulate T cells ex 
vivo.  If our hypothesis is correct and CD169+ TAMs do stimulate antitumor T cells, therapies 
aimed at increasing this TAM subpopulation may greatly impact cancer progression or 
responsiveness to other cancer immunotherapies.   
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